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ABSTRACT
Sphingolipids are widely expressed molecules, which traditionally were considered to 
have majorly structural properties. Nowadays, however, they are implicated in a wide 
range of different biological processes.  The bioactive lipid sphingosine 1-phosphate 
(S1P) has emerged during the past decade as one of the most studied molecules due 
to its proliferative and pro-migratory abilities both during normal physiology and in 
the pathology of a subset of different diseases. Migration and invasion of cancer cells 
require changes in cell behavior and modulation of the tissue microenvironment. 
Tumor aggressiveness is markedly enhanced by hypoxia, in which hypoxia inducible 
transcription factors 1-2α (HIF-1-2α) are activated to promote metabolism, proliferation 
and migration. Invasion requires degradation of the extracellular matrix (ECM) achieved 
by several degrading and remodeling enzymes. Matrix metalloproteinases (MMPs) are 
broadly expressed and well accepted as proteolytic enzymes with essential roles both in 
normal physiology and in pathology. 
Previously, S1P was shown to strongly evoke migration of follicular ML-1 thyroid 
cancer cells. The objective of this study was to further investigate and understand the 
mechanisms behind this regulation. In the first project it was demonstrated that S1P 
enhances the expression and activity of HIF-1α. S1P enhanced the expression of HIF-1α 
by increasing its synthesis and stability. The S1P-increased HIF-1α was mediated via 
S1P3, Gi/0, PI3K, PKCβI, ERK1/2, mTOR and translation factors p70S6K and eIF4E. 
Finally, it was shown that HIF-1α mediated S1P-induced migration. 
The ECM is constituted of a complex and coordinated assembly of many types 
of proteins. In order to be able to invade, cells need to break down the ECM, therefore 
several key players in this event were investigated in the second project. S1P increased 
the secretion and activity of MMP2 and MMP9 via S1P-receptor 1 and 3 and that these 
MMPs participated in the S1P-facilitated invasion of ML-1 cells. In this interplay, 
calpains and Rac1 were involved, both of which are crucial players in migration and 
invasion.
The prognosis for some types of thyroid cancer is relatively good. However, there 
are forms of thyroid cancers, for which there are no treatments or the current available 
treatments are inefficient. Thus, new medical interventions are urgently needed. In the 
third project the significance of the S1P-receptor modulating drug FTY720, which is 
currently used for the treatment of multiple sclerosis (MS), was studied. The effect of 
FTY720 was tested on several thyroid cancer cell lines, and it inhibited the proliferation 
and invasion of all cancer cell lines tested. In ML-1 cells, FTY720 attenuated invasion 
by blocking signaling intermediates important for migration and invasion of the cells. 
Moreover, FTY720 inhibited the proliferation of ML-1 cells by increasing the expression 
of p21 and p27, hence, inducing cell arrest in G1 phase of the cell cycle. Thus, it can be 
suggested that FTY720 could be used in the treatment of thyroid cancer. 
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Sphingosine-1-phosphate (S1P) is a bioactive lipid with the ability to induce migration, 
invasion, proliferation and angiogenesis. Thus, S1P plays a fundamental role in tumor 
biology.  S1P elicits its effects by binding to one of its five highly specific G-protein 
coupled receptors termed S1P1-5 and activating different G-proteins. Worth keeping in 
mind is that the ultimate outcome of the S1P stimulation, however, depends completely 
on the S1P receptor and the type of G-protein it activates. Thus, S1P can give rise to both 
stimulatory and inhibitory responses. In endocrine organs, thyroid cancer is one of the 
most commonly occurring types of cancer. Our group has for almost a decade studied 
the effect of S1P on several cellular processes in several thyroid cancer cell lines. We 
showed earlier that S1P very strongly enhances the migration of the follicular ML-1 
thyroid cancer cells via S1P1,3 and Gi/0 proteins. In this regulation the vascular endothelial 
growth factor receptor 2 (VEGFR2) plays an essential role. Thus, a cross-talk between 
these two receptor systems exists in ML-1 cells.
Tumor environment is usually hypoxic, thus tumor cells suffer from oxygen 
deficiency, a condition extremely unfavorable to the cancer cells. Hence, lack of oxygen 
could in fact be very fatal to the cells. However, cancer cells have tackled this problem by 
inducing a family of hypoxia inducible transcription factors (HIF-1-2α), which enhance 
metabolism and survival of the cancer cells. HIF-1α has gained a substantial amount of 
attention due to its ability to activate a subset of different genes promoting cancer cell 
survival, proliferation, migration, invasion and angiogenesis.
One hallmark of tumor biology is invasion, which is a multistep process requiring 
changes in cell behavior and in the environment around the tumor and the invading 
cell. The first requirement for a cell to be able to invade is loss of cell-cell and cell-
extracellular matrix (ECM) contacts. Hence, invasion requires degradation of the ECM, 
in which matrix metalloproteinase (MMPs) act as one of the main governors.  
The pro-angiogenic molecule S1P has been shown in different studies to enhance 
tumor growth and metastasis of several types of cancers by modulating key players 
in these cellular processes. Thus, inhibition of S1P receptors has become an attractive 
target in the treatment of different diseases. Currently, several different S1P-receptor 
modulating drugs are in clinical trials. However, only FTY720 has successfully reached 
clinical practice for the treatment of multiple sclerosis (MS). Nonetheless, FTY720 has 
been tested in cancer cells, and it is found that it inhibits both migration and proliferation 
of cancer cells, representing new therapeutic strategies and clinical advantages.  
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2. REVIEW OF THE LITERATURE
2.1 Thyroid structure and function
As one of the largest endocrine organs, the thyroid gland is situated on the anterior 
side of the neck. It is composed of two lobes (left and right) connected with each 
other via an isthmus (a wall between the two lobes). Within the posterior region of 
the gland four small parathyroid glands responsible for the production of parathyroid 
hormones (PTH) can be found. Two types of cells can be found in the thyroid tissue: 
follicular cells, also called thyrocytes, producing thyroxin (T4) and triiodothyronine 
(T3) hormones, and parafollicular cells, which produce calcitonin. Due to its ability 
to produce hormones influencing many central functions in the body, the thyroid 
gland is considered one of the master regulators of biological processes, particularly 
during development and childhood (Stathatos, 2012). Figure 1 shows the structure and 
location of the thyroid gland.
Figure 1. The thyroid gland is situated in the anterior region of the neck, containing four posterior 
small parathyroid glands. (Adapted and modified from http://www.cancer.gov/types/thyroid/
patient/thyroid-treatment-pdq#section/all).
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The main function of calcitonin is to regulate the metabolism of calcium. Calcitonin acts 
to decrease the Ca2+ ion concentrations in the blood by different means; it modulates 
the osteoblastic and osteoclastic activity in the bone, inhibits intestinal absorption of 
Ca2+ and stimulates the excretion of Ca2+ by the kidney due to its ability to inhibit the 
renal tubular cell reabsorption of Ca2+. In contrast to calcitonin, PTH acts to increase 
the concentrations of Ca2+ in the blood. However, PTH itself is regulated via a negative 
feedback loop, meaning that high concentrations of blood Ca2+ prevent the secretion of 
PTH (Economidou et al., 2011).
The thyroid hormones T3 and T4 are produced from iodine and thyroglobulin 
by the follicular cells. These hormones are involved in regulation of body metabolism, 
protein synthesis, thermoregulation and development, in particular the development 
of the brain. The thyroid-stimulating hormone (TSH) generated and released by the 
anterior pituitary regulates the synthesis and release of T3 and T4. T4 is synthesized 
upon iodination of thyroglobulin by the action of thyroperoxidase. However, T4 is the 
inactive hormone, which in response to deiodinase is converted to the active T3 in the 
blood (Economidou et al., 2011).
2.1.1 Thyroid diseases
As any other organ of the body, also the thyroid gland is subject to several different types 
of abnormalities and malfunctions, ranging from a harmless enlargement of the gland 
(goiter) to highly malignant and deadly cancers. The disorders that strike the thyroid 
gland are hyperthyroidism, hypothyroidism, thyroiditis, thyroid nodules and cancers 
(Hong et al., 2015).  
Hyperthyroidism is characterized by excessive amounts of thyroid hormones. 
In general, hyperthyroidism originates from Graves’disease, which is an autoimmune 
disorder. In this condition, the body produces high amounts of thyroid-stimulating 
antibodies resulting in excessive production of thyroid hormones. In contrast to 
hyperthyroidism, hypothyroidism occurs commonly due to insufficient production of the 
thyroid hormones because of a dysfunctional thyroid gland. However, this disorder can 
also appear due to iodine deficiency or the autoimmune disease Hashimotos thyroiditis. 
Furthermore, there are many other factors causing hypothyroidism such as injury to 
the hypothalamus or the anterior pituitary and previous surgical removal of the thyroid 
gland. Other types of abnormalities found in the thyroid gland are thyroiditis and goiter. 
Thyroiditis is an infection of the thyroid tissue caused by bacteria, fungi and viruses 
mostly affecting children, but also adults can suffer from this disorder. Goiter, which is 
detected in the front of the neck, is a condition where the thyroid gland is enlarged due to 
iodine deficiencies and malfunctions of the thyroid gland. Goiter is a harmless condition 
when treated properly, however, it can be toxic to the patient (Hong et al., 2015).
2.1.2 Thyroid nodules and neoplasms
Thyroid cancer is the most common type of malignancy affecting the endocrine organs, 
and the thyroid cancer incidences have increased significantly worldwide during the 
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past decades. Females are known to be more prone to thyroid cancer diseases than men, 
perhaps due to the female hormones. The reasons for thyroid cancer occurrence are 
poorly understood. However, many predisposing risk factors have been associated with 
the disease and are considered to contribute to the development of thyroid cancers. The 
risk factors include family history, iodine deficiency, exposure to radiation gender and 
age. In addition to these risk factors, inflammation conditions in the thyroid gland can, if 
not properly treated in time, lead to development of cancers  (Kondo et al., 2006; Jin et 
al., 2013; Hong et al., 2015).
Usually the thyroid tissue contains small benign nodules, however, they are found 
quite rarely in the thyroid gland of persons under the age of 20. Thus, when found at the 
age of 20, the nodules have a higher likelihood of becoming malignant. Often the thyroid 
nodules present in the thyroid gland are detected by coincidence, either by the patient 
itself or the physician. However, with advanced modern technology and the knowledge 
in the field of tumor biology, we have better diagnostic tools for the detection and the 
identification of thyroid cancer. The most common ways to diagnose thyroid neoplasms 
are blood tests, ultrasound imaging and fine needle biopsies (FNB). The first symptoms 
of thyroid cancer are enlarged lymph nodes, which is followed by pain in the anterior 
side of the neck and hoarseness  (Kondo et al., 2006; Jin et al., 2013; Hong et al., 2015).
There are many types of thyroid cancer, ranging from very easy-treating forms to 
life threatening and deadly ones. The classification of the thyroid carcinomas is based 
on the origin, stage and degree of metastasis. The thyroid cancer diseases are divided 
into three main groups consisting of medullary thyroid carcinomas (MTC), anaplastic 
thyroid carcinomas (ATC) and differentiated thyroid carcinomas (DTC). DTC consists 
of two subtypes: follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma 
(PTC).  The distinct characteristics for the particular types of thyroid cancers are the 
degree of differentiation and the mutations occurring in genes specific for them (Xing, 
2013).
2.1.2.1 Papillary thyroid carcinoma (PTC)
PTC is the most common type of thyroid cancer with increased incidences attributing to 
the overall increase in thyroid cancer diseases. PTC is highly differentiated and originates 
from the follicular thyroid cells accounting for approximately 85% of all thyroid cancer 
cases. Patients with PTC have a favorable and good overall prognosis (Jin et al., 2013). 
Biomarkers and molecular and genetic alternations for PTC have been identified. The 
most frequent gene alternation in PTC is the BRAF V600E mutation occurring in almost 
45% of the patients (Nikiforov et al., 2011). Frequent rearrangements in the rearranged 
during transfection (RET) gene is found in patients with PTC due to the interactions 
between the intracellular tyrosine kinase domain of RET and the N-terminal domain of 
various target genes (Nikiforov, 2008). Both RET rearrangements and BRAF V600E 
mutations lead to a constitutive stimulation of the mitogen-activated protein kinase and 
extracellular regulated kinase 1/2 (MAPK/ERK1/2) pathway, enhancing cellular growth 
and metastasis (Nikiforov et al., 2008 and Nikiforov, 2011). 
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2.1.2.2 Follicular thyroid carcinoma (FTC)
Being the second most frequently occurring type of thyroid cancer, FTC accounts 
for almost 11% of all thyroid malignancies in countries with iodine sufficiency, and 
approximately 25-40% in iodine-insufficient areas. The overall prognosis for patients 
with FTC is good. FTC has its origin in the follicular thyroid cells and is highly 
differentiated (Jin et al., 2013). FTC has been studied at molecular level, and it has been 
demonstrated that gene alternations play a crucial role in the pathogenesis of FTC. Both 
mutations and chromosomal translocations can occur in FTC causing uncontrolled cell 
growth and proliferation. The most common mutations occur in the RAS-family genes 
(N-RAS, K-RAS and H-RAS). These mutations are detected in approximately 40% of 
the patients. Mutations in RAS are normally associated with uncontrolled growth and 
proliferation (Downward, 2003). In addition, mutations in p53, c-myc, fos, TSH and 
the PTEN suppressor gene increase the likelihood for occurrence of FTC (Fuhrer et 
al., 2003).  Paired box gene 8 (PAX-8) encodes the peroxisome proliferator-activated 
receptor ϒ (PPARϒ1), and it is important for thyroid cell growth. In approximately 
50% of all cases rearrangements in PAX8/PPARϒ1 has been detected and associated 
with uncontrolled cell growth (Martelli et al., 2002). Apart from mutations and gene 
translocations, numerous studies have demonstrated enhanced expression of MicroRNAs 
in FTC, altering gene transcription and influencing cell proliferation and apoptosis 
(Weber et al., 2006).
2.1.2.3 Anaplastic thyroid carcinoma (ATC)
ATC is considered as one of the most aggressive types of cancers affecting the human 
body.  It is rare and represents only about 2% of all thyroid cancer cases. ATC is extremely 
pathogenic associated with poor prognosis and high degree of mortality (Smallridge 
& Copland, 2010). The survival rate for patients with ATC is extremely low. In most 
cases patients with ATC have 1-year survival. However, in rare cases patients might 
survive for 5 years (Broome et al., 2009). ATC derives from de-differentiations of FTCs 
and PTCs. However, it does not harbor any functional characteristics of its descendent, 
the follicular cell. Furthermore, ATCs can develop from head and neck squamous cell 
carcinomas due to the differentiation ability of transcription factor PAX8 (Bishop et al., 
2011). As with the other types of thyroid carcinomas, ATCs harbor genetic alternations 
such as mutations in the genes involved in growth, metastasis and apoptosis. Usually, 
mutations are found in the genes for p53, RAS, BRAF, the E3 ubiquitin-protein ligase 
(MIB-1), axin 1, β-catenin and phosphoinositide 3-kinase (PI3K) (Smallridge, 2012). In 
addition, overexpression of cyclins D1 and E1 has been observed in ATC, boosting cell 
growth (Kondo et al., 2006). 
2.1.2.4 Medullary thyroid carcinoma (MTC)
MTC originates from the parafollicular C cells responsible for the production of 
calcitonin, thus, highlighting the suitability of calcitonin levels as a marker for MTC. 
MTCs occur very rarely and account for approximately 5% of all thyroid cancer 
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incidences. It has a good prognosis when detected in time and the overall survival 
rate is 5-10 years. However, a poor prognosis is associated with advanced age of the 
patient, the stage of the tumor, multiple endocrine neoplasia 2B (MEN 2B) and previous 
neck surgery (van Veelen et al., 2009; Krampitz & Norton, 2014). MTCs can occur 
sporadically, however, 25% of all reported MTC cases are family-related.  Familial MTC 
emerges as a consequence of familial multiple endocrine neoplasia, MEN 2A and MEN 
2B and also familial non-MEN syndrome.  Furthermore, alternations in the RET gene 
have been detected in patients with MTC, and family members of MTC patients are 
encouraged to undergo examinations and DNA-testing for mutations in the RET gene to 
secure diagnosis at an early stage as possible (Krampitz & Norton, 2014). 
2.2 Tumor transformation, migration and invasion
Giving the complexity of biological processes, cell migration is one of the most 
interesting phenomena of a living cell, involving several distinct steps, which are 
orchestrated by a subset of different regulatory mechanisms. Cell migration requires 
reshaping of the cell accomplished by cytoskeletal rearrangements as well as formation 
of membrane structures, such as lamellipodia and filopodia. The first step of migration 
is formation of a front (leading) edge and a rare (back) of the cell. Within the leading 
edge actin polymerization is thought to be the main force driving the cell forward. The 
small GTPases CDC42 and Rac1 are usually found in the leading edge, whereas RhoA is 
found in the rare side of the cell (trailing edge). Within the leading edge focal adhesions 
assemble, while disassembly takes place in the trailing edge. These processes involve the 
action of adhesion proteins and proteolytic enzymes (Labelle & Hynes, 2012; Vanharanta 
& Massague, 2013; McAllister & Weinberg, 2014; Sevenich & Joyce, 2014).
Tumorigenesis is a process where normal cells acquire features characteristic for 
cancer. Epithelial to mesenchymal transition (EMT) is one hallmark of this transformation, 
in which cells acquire properties that offer extremely favorable conditions to the 
transformed cells for survival. After years of investigations, it is now becoming more 
evident that cells that undergo EMT exhibit features similar to stem cells (Labelle & 
Hynes, 2012; Vanharanta & Massague, 2013; McAllister & Weinberg, 2014; Sevenich 
& Joyce, 2014).
Metastasis is a multistage process involving alternations of the tumor 
microenvironment. The process comprises several critical events such as loss of cell-cell 
and cell-extracellular matrix (ECM) contacts, degradation of the basement membrane 
and the ECM, as well as adhesion at the site of the newly invaded tissue. Integrins and 
cadherins are adhesion proteins influencing the intimate contacts between cells and cell-
ECM. In order to be able to migrate from the tissue of origin, cells need to brake down 
the extracellular matrix. This process requires the involvement of diverse biochemical 
events and signaling molecules. The journey of the invasive tumor cell is very complex. 
After loss of cell contacts and the proteolysis of the ECM, cells first intravasate into 
blood vessels and are transported away from the tissue of origin via the blood. Later on 
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cells escape from the blood vessels, a process called extravasation.  Nonetheless, tumor 
dissemination and metastasis can also occur through lymphogenesis.  Most importantly, 
the final step of invasion is colonization, meaning adherence of the cells to the newly 
invaded tissue. At this stage the invasive tumor cells undergo a critical period due to 
their need for nutrition and survival. Thus, formation of new blood vessels, a process 
termed angiogenesis, is very vital (Labelle & Hynes, 2012; Vanharanta & Massague, 
2014; McAllister & Weinberg, 2013; Sevenich & Joyce, 2014).
2.3 Sphingolipid metabolism
Sphingolipids, also called glycosylceramides, were found already in 1870s. They are 
a group of lipids containing a conserved aliphatic amino alcohol sphingoid backbone. 
They were first identified as structural components of lipid membranes. However, later 
on, a great deal of attention was attributed to the sphingolipids due to their fundamental 
and diverse functional roles in biological processes in the cell.  They are also important 
phospholipid species in the structure of all plasma lipoproteins.
The bioavailability of sphingolipids is dependent on the unique inter-conversion of 
the existing metabolites within the sphingolipid group. The biosynthesis of sphingolipids 
is a result of several highly distinct and complex steps of metabolic reactions tightly 
regulated by degrading and generating enzymes (Alshaker et al., 2013; Zu Heringdorf 
et al., 2013). The starting point of the sphingolipid catabolism is sphingomyelin, the 
major representative among sphingolipids. Sphingomyelin is converted to ceramide 
by the action of sphingomyelinase. Ceramide is considered a central metabolite in the 
metabolism of sphingolipid, and can also be formed from condensation of palmitate 
and serine. Sphingomyelinsyntases are responsible for the conversion of ceramide to 
sphingomyelin. The pro-apoptotic sphingosine is generated from ceramide, a reaction 
catalyzed by ceramidases. Sphingosine-1-phosphate (S1P) is generated as a result of 
phosphorylation of sphingosine by the action of sphingosine kinases 1 and 2 (SK1 and 
SK2). Depending on the circumstances, S1P can either be converted back to sphingosine 
by S1P phosphatases, or irreversibly degraded by S1P lyases to palmitaldehyde 
(hexadecenal) and ethanolamine phosphate species (Pyne & Pyne, 2013; Kerage et al., 
2014; Mendelson et al., 2014). 
Several years of research and lines of evidence have demonstrated an extremely 
important role of the sphingolipids in cell function. Particularly, sphingosine, ceramide 
and S1P are considered master regulators of cell fate. Hence, a rheostat has been 
suggested with sphingosine and ceramide driving cells into death, and S1P inducing 
cell proliferation and survival. As can be expected, any disruption in the sphingolipid 
metabolic pathway can have serious consequences. Therefore, each and one of the 
components involved in the pathway are regulated very tightly (Pyne & Pyne, 2013; Zu 
Heringdorf et al., 2013; Kerage et al., 2014;).  Figure 2 summarizes the major players in 
the sphingolipid metabolism. 
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Figure 2. Sphingolipid metabolism. The figure shows different steps and conversions of bioactive 
sphingolipids. (Adapted from Pyne & Pyne, 2013).
2.3.1 Sphingosine-1- phosphate and its receptors
2.3.1.1 Sphingosine-1-phosphate 
Virtually all types of cells in the body can produce sphingosine-1-phosphate (S1P), 
however, the main sources of S1P are platelets, erythrocytes and immune cells. Upon 
production, S1P is transported out from the cell by the aid of several transporters in the 
plasma membrane (Figure 3 demonstrates the structure of S1P). The ATP-binding cassette 
transporters (ABC) and spinster 2 (spins 2) are the most known and studied transporters 
of S1P. S1P is presented in high concentrations in the blood and plasma, usually bound to 
lipoproteins and albumin (Sattler & Levkau, 2009; Rodriguez et al., 2009). The intracellular 
S1P concentration is very low, but the concentration of S1P in the extracellular milieu 
is high. These differences in the concentration of S1P generate a S1P gradient, which is 
important for the action of S1P (Strub et al., 2010; Takabe & Spiegel, 2014).
S1P has been associated with a wide range of different cellular processes both 
during development and progression of many diseases. During development S1P 
contributes to the formation of many organs. The most obvious role of S1P is in the 
development of the vasculature, the heart and the nervous system. Vascularization is 
important for the survival of cells and is one hallmark of angiogenesis, in which S1P 
plays a pivotal role by inducing VEGF secretion and VEGFR2 activation. S1P plays an 
important role even in inflammation and immunological conditions. Furthermore, S1P 
is frequently overproduced as a consequence of hyperactivity of SK in several cancer 
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cells. Thus, S1P influences the behavior of cancer cells by inducing their proliferation 
and migration (Strub et al., 2010; Takabe & Spiegel, 2014).
Recently intracellular targets of S1P have been identified, demonstrating S1P as a 
secondary messenger in the cells (Nagahashi et al., 2014). The S1P produced by nuclear 
SK2 can regulate transcription by binding to and, consequently, inhibiting the histone 
deacetylases (HDAC1 and HDAC2) (Hait et al., 2009).
Furthermore, the S1P produced by SK1 has been shown to have two intracellular 
targets involved in cellular growth and apoptosis. S1P has been demonstrated to bind to 
tumor necrosis factor receptor factor 2 (TRAF2), and to act as a crucial cofactor essential 
for the activity of E3 ubiquitin ligase (Alvarez et al., 2010). Moreover, cellular inhibitor 
of apoptosis 2 (cIAP2) is a target of intracellular S1P. The mechanism of action is that 
S1P binds to and enhances the activity of cIAP2, subsequently leading to inhibition of 
apoptosis (Harikumar et al., 2014).
2.3.1.2 S1P associated with lipoproteins in serum
S1P is present in serum bound to lipoproteins. Around 60% of S1P is bound to HDL 
and 10% to LDL and VLDL. The remaining 30% of S1P is carried in albumin. HDL 
present in plasma contains several different apolipoproteins, of which apolipoprotein M 
is a crucial component in the binding of S1P to HDL (Rodriguez et al., 2009; Karunar 
et al., 2011; Christoffersen et al., 2011; Bas et al., 2013). Importantly, high levels of 
plasma apolipoprotein M have been linked to elevated levels of S1P, and this correlation 
has been suggested to play a role in the anti-atherosclerotic properties of both S1P and 
apolipoprotein M  (Bas et al., 2013). 
Extensive studies have demonstrated that the beneficial effects of HDL, at least 
in endothelial and vascular smooth muscle cells of the vasculature, are dependent on the 
S1P that is bound to HDL. HDL-bound S1P has been shown to confer vasculoprotection 
by inducing the release of nitric oxide and prostacyclin. The release of nitric oxide 
involves Akt-dependent phosphorylation of endothelial nitric oxide synthase, while 
the prostacyclin release engages activation of cAMP response element binding protein 
(CREB) mediated by ERK1/2 and p38 mitogen activated protein kinase. The induction 
of nitric oxide and prostacyclin by HDL-S1P are of importance in the regulation of 
many cellular events, such as proliferation, apoptosis, cell adhesiveness, angiogenesis 
and vascular integrity (Rodriguez et al., 2009). 
Figure 3. The structure of sphingosine-1-phosphate. (Adapted and modified from http://commons.
wikimedia.org/wiki/File:Sphingosine_1-phosphate.svg). 
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2.3.2 S1P-receptors and mechanism of action
S1P-receptors are a group of G-protein coupled receptors (GPCR) with seven 
transmembrane helices. Upon activation by their extracellular ligand, GPCRs activate 
a subset of different G proteins, ultimately leading to stimulation of downstream 
signaling pathways and a diverse array of cellular responses. After several years 
of extensive studies, five highly specific S1P-receptors termed S1P1-5, have been 
identified (Pyne & Pyne, 2013). Almost all types of cells express all or some of the 
S1P-receptors. Extracellular S1P, such as that associated with HDL-apolipoprotein M, 
binds S1P-receptors, resulting in activation of different G proteins, and downstream 
signaling intermediates. However, the outcome of this cascade activation is 
exclusively dependent on which S1P-receptor and G protein is activated. Hence, S1P-
receptors have both opposing and overlapping functions, which is coupled to their 
distinct G proteins. A substantial amount of evidence has proven S1P/S1P-receptors 
to be of fundamental importance in physiological processes during development, 
and also during pathophysiology and progression of many different diseases. Thus, 
understanding the nature and mode of action of these receptors is of great importance 
(Dorsam & Gutkind, 2007). The mode of action for the different S1P-receptors is 
demonstrated in Figure 4. 
2.3.2.1 S1P1
S1P1 is the first receptor cloned, and it is expressed in almost all types of tissues, especially 
in cerebellum and immune cells. Its function, however, has been studied thoroughly in 
immune cells (Garris et al, 2014). It is a stimulatory receptor highly associated with 
induction of migration, proliferation, calcium signaling, angiogenesis, invasion and 
cell survival of both cancerous and non-cancerous cells (Tabasinezhad et al., 2013). 
Binding of S1P to S1P1 leads exclusively to activation of Gi/0 resulting in activation of 
PI3K and Akt pathway, the master regulators of survival of several cell types (Garris 
et al, 2014). S1P via the same receptor and pathway is able to inhibit H2O2-induced 
apoptosis of granulosa cells (Nakahara et al., 2012). Moreover, S1P1 influences cell 
proliferation by activating RAS and ERK1/2, while it induces migration and invasion 
via activation of PI3K and Rac1 (Tabasinezhad et al., 2013). Furthermore, in multiple 
sclerosis (MS) lesions the expression of S1P1 is up-regulated in astrocytes indicating 
that astrocytes might function as a new target of anti-inflammatory drugs (Van Doorn et 
al., 2010). Several lines of evidence have shed light on the collaboration between S1P1 
and growth factors. In endothelial cells, S1P is able to activate growth factor receptors 
as well as to enhance the secretion of growth factors such as VEGF, EGF, PDGF, and 
bFGF (Tabasinezhad et al., 2013). It is well documented that S1P1 activates integrins to 
modulate adhesion. S1P1 plays a fundamental role also in modulating the extracellular 
matrix by affecting several crucial players important for this event. Thus, from a cancer 
perspective, S1P1 is considered a driving force of tumorigenesis (Tabasinezhad et al., 
2013; Pyne & Pyne, 2013). 
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2.3.2.2 S1P2
Almost all types of cells express S1P2, and in contrast to other S1P receptors it has 
been demonstrated to exert inhibitory effects on a multitude of biological processes. 
The engagement of different biological responses downstream from S1P2 signaling 
is amplified through activation of Gi/0, Gq and G12/13. Nonetheless, S1P2 has strongly 
been correlated with decreased migration, proliferation, angiogenesis and adhesion 
(Adada et al., 2013). It is well established that S1P2 causes stress-fiber formation and 
disruption of adherens junctions, which leads to inhibition of endothelial cell migration. 
This response was found to be dependent on activation of Rho and Rho-associated 
protein kinase (ROCK) and subsequently inhibition of the PI3K pathway (Sanchez et 
al., 2007). It is worth to keep in mind that S1P2 simultaneously inhibits Rac1 leading 
to anti-migratory responses (Arikawa et al., 2003). Moreover, macrophage migration 
is inhibited by the action of S1P2 through enhanced cyclic adenosine monophosphate 
(cAMP) production and activation of protein kinase A (PKA) (Michaud et al., 2010). 
Several lines of evidence have associated S1P2 with proliferation. In Wilm’s tumor cells 
(WiT49 cells) S1P inhibits proliferation via S1P2 (Li et al., 2008).  The anti-proliferative 
action of S1P2 is strengthened by results from animal and patient studies. Mice lacking 
S1P2 exhibit diffuse large B-cell lymphomas, and patients with such symptoms were 
found to harbor a mutation in their S1P2 gene. Thus, lack of S1P2 or mutations in the 
S1P2 gene result in enhanced cell growth, illustrating the inhibitory effects of S1P2 on 
proliferation (Cattoretti et al., 2009).
2.3.2.3 S1P3
S1P3 can be found on the surface of virtually all types of cells, however, its expression 
is highest in the heart, lung and spleen. Functionally S1P3 has been associated with 
the same kind of responses as S1P1. S1P3 activates Gi/0, Gq and G12/3, and gives rise to 
cellular responses linked to proliferation, migration and angiogenesis. The final result 
of S1P3 response is thus dependent on the cell type and which G protein is activated. 
S1P3 has been closely associated with inflammation, and it has been suggested that 
it would function as a potential biomarker in lung injuries (Sun et al., 2012).  The 
role of S1P3 is also evident in MS, in which it together with S1P1 is up-regulated in 
astrocytes causing inflammation in the brain. Thus, in MS, drugs targeting S1P3 could 
be beneficial  (Van Doorn et al., 2010). In contrast to its stimulatory effects, S1P3 can 
act as an inhibitor of cellular events. S1P3 has been correlated with anti-migratory and 
anti-proliferative effects during arterial injury. These notions originate from studies, 
in which defects in S1P3 have resulted in an increased amount of smooth muscle 
cells in atherosclerotic lesions, pointing to an inhibitory role for S1P3 (Keul et al., 
2011).  Furthermore, S1P by activating S1P3 is able to decrease coronary blood flow 
(Murakami et al., 2010). Nonetheless, the function of S1P3 is not restricted to normal 
cells S1P3 plays an important role in cancers as well. In lung cancers, S1P3 has been 
shown to collaborate with endothelial growth factor (EGF) receptor system to regulate 
proliferation and migration (Hsu et al., 2012) and in breast cancer S1P3 in response to 
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estrogen is able to trans-activate EGF-receptor to regulate migration and proliferation 
(Sukocheva et al., 2006).
2.3.2.4 S1P4
S1P4 activates Gi/0 and G12/13, albeit with a preference for Gi/0. The expression of 
S1P4 is restricted to specific tissues such as lymphoid organs. As can be expected 
the knowledge we have gained about the nature and function of S1P4 comes from 
studies mostly obtained from these tissues. Thus, to expand our understanding about 
the importance of S1P4, more investigations need to be performed. Nevertheless, there 
are some reports showing both stimulatory and inhibitory responses triggered by this 
receptor. Overexpression of S1P4 has been shown to have opposing effects in different 
cell types. In Chinese hamster ovary cells S1P4 overexpression causes stress-fiber 
formation, hence, inhibition of migration coupled to Gi/0 and G12/13, highlighting an 
inhibitory effect of S1P4 (Graler et al., 2003). T-cells expressing S1P4, but depleted of 
S1P1, lacked the capacity to migrate, suggesting S1P4 to have no major importance for 
migration. However, results obtained from the same cells showed that S1P via S1P4 
was able to inhibit proliferation (Wang et al., 2005). In contrast to those results, the 
migration of Jurkat T cells was induced when S1P4 was overexpressed, even in the 
absence of S1P (Graler et al., 2003). Thus, these reports suggest that the responses 
triggered by S1P4 are cell type specific.
2.3.2.5 S1P5
S1P5 activates exclusively Gi/0 and G12/13. In a tissue screen study by Im and coworkers 
(2001) S1P5 was found in a variety of different tissues including spleen, lung, placenta, 
aorta and peripheral blood leukocytes. However, high expression of S1P5 can be 
mainly observed in the brain, where S1P5 has been mostly studied. S1P5 has been 
implicated in impeding migration of immature oligodendrocytes via Rho (Novgorodov 
et al., 2007), whereas survival of mature oligodendrocytes is stimulated by S1P5 in a 
Gi/0 and AKT-dependent fashion. These results suggest that S1P5 might function as a 
regulator of different developmental stages (Jaillard et al., 2005). Furthermore, S1P5 
has been demonstrated to play a fundamental role in maintaining the blood-brain 
barrier by decreasing permeability and increasing tight junctions. S1P5 also decreases 
inflammation by inhibiting NF-kB activation and subsequent cytokine secretion as 
well as by decreasing transendothelial migration into brain parenchyma (Van Doorn 
et al., 2012).  
Apart from its role in normal cell function, S1P5 has also been shown to be 
involved in cancer cell behavior. Chang et al. (2009) reported that in prostate cancer 
cells S1P induced autophagy via S1P5, demonstrating that this receptor plays an 
inhibitory role in proliferation and survival. In another study by Hu et al. (2010) in 
esophageal cancer cells overexpressing S1P5, S1P-stimulation resulted in inhibition 
of proliferation and migration. Interestingly, S1P5 overexpressing esophageal cancer 
cells were able to migrate more in the absence of S1P compared to cells expressing 
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empty vector. This observation led the authors to assume that esophageal cancer 
cells might in fact down-regulate S1P5 to escape the inhibitory effect of S1P5 (Hu 
et al., 2010). Collectively, based on the above-described results S1P5 might function 
as an inhibitory receptor, giving rise to inhibition of cellular responses. However, to 
broaden our view more investigations dealing with the actions of this receptor must 
be performed. Equally important is the need for results from different cell types and 
animal studies.
Figure 4. S1P-receptors and their downstream signaling events are depicted here. Depending 
on which receptor and G protein is activated, S1P stimulation elicits different cellular pathway 
responses. (Adapted and modified from Pyne & Pyne, 2013).
2.4 Sphingosine kinases in cancer
Two isoforms of sphingosine kinases termed SK1 and SK2 exist. Despite similarities in 
their structure, they exhibit differences in localization and function (Selvam & Ogretmen 
2013). 
SK1 is cytosolic and signals proliferation and migration. SK1 expression has 
been found to be up-regulated in many types of cancers correlating with an invasive 
phenotype of the cancer cells. However, no mutation in the SK1 gene has been found, 
suggesting that it is rather the SK1 activity that is enhanced during tumorigenesis. Many 
lines of evidence have implicated SK1 in tumor growth and metastasis, and in fact, 
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SK1 has been considered as an oncogene. As both high levels of S1P and elevated SK1 
activity cause resistance to cytotoxic drugs and radiation, inhibition of SK1 has been 
proven beneficial in increasing the sensitivity of cancer cells to radiotherapy (Selvam 
& Ogretmen 2013; Newton et al., 2015). SK1 becomes activated via several signaling 
molecules. Protein kinase C (PKC) has been strongly associated with phosphorylation of 
SK1. PKC phosphorylates SK1 and triggers SK1 translocation to the plasma membrane. 
In addition, SK1 and VEGF have been shown to communicate, and this interplay might 
play an important role in cancer. VEGF is able to increase SK1 activity and SK1 is 
able to stimulate VEGF secretion, which of course is important in angiogenesis and 
vascularization (Tabasinezhad et al., 2014). VEGF-induced phosphorylation of SK1 
triggers activation of RAS, ERK1/2-MAPK and subsequently cellular responses  (Hait 
et al., 2006). There are several SK1 inhibitors, which have been shown to elicit excellent 
effects on tumor growth, angiogenesis and metastasis (Selvam & Ogretmen, 2013; 
Tabasinezhad et al., 2014).  
SK2 is mainly found in the nucleus and cellular compartments and acts as a pro-
apoptotic molecule. However, SK2 has recently been found to confer drug resistance, 
thus a role for SK2 in cancer is emerging. The SK2 inhibitor ABC294640 has been 
shown to inhibit growth and proliferation of many types of cancer cells, and to increase 
sensitivity to chemotherapy  (Selvam & Ogretmen, 2013; Newton et al., 2015).  In 
vitro, ABC294640 has been reported to induce autophagy and inhibits chemo-resistance 
mediated by NF-kB in breast cancer, thus ABC294640 has anti-estrogenic effects. 
Additionally, ABC294640 used with other inhibitors and drugs have shown additive 
effects on cancer cell proliferation. In fact, ABC294640 has reached phase 1 of clinical 
trials, where patients with advanced tumors are treated with this drug (Zu Heringdorf, 
2013). 
2.5 Hypoxia-inducible factors
Hypoxia-inducible factors (HIF) are a family of hypoxia inducible transcription 
factors consisting of three members termed HIF-1, HIF-2 and HIF-3, which are 
activated in response to low oxygen levels. HIFs are composed of two subunits: 
one alpha (α) and one beta (β) subunit. The HIFβ subunit (also called ARNT) is 
constitutively active, while the HIFα subunit is subject to regulation by different 
means (Ke & Costa, 2006). The HIF-1α and β subunits consist of several similar 
domains each with distinct function. The N-terminal domain functions as DNA-
binding site, the central region (PAS 1 and 2) serves as hetero-dimerization domain 
and the C-terminus is used for recruitment of transcriptional co-activators. In addition 
to these domains, the alpha subunit contains an oxygen dependent degradation 
domain (ODDD), which plays an essential role in oxygen-dependent degradation of 
HIF-α (Ke & Costa, 2006; Ortmann et al., 2014). Figure 5 summarizes the structure 
of the HIF-1α subunit.
 Review of the Literature 23
Figure 5. Schematic picture that shows the structure of HIF-1a with several domains. Each 
domain has a specific function. The bHLH domain within the N-terminus of the protein functions 
as DNA-binding site, the PAS domain is the site where HIF-1β (ARNT) binds. The TAD domain 
is the binding site for PHDs, a binding that triggers O2 dependent degradation. The C-terminus 
TAD domain recruits co-activators (CBP/p300), which are important in target gene activation. 
(Adapted from Semenza, 2003).
2.5.1 HIF-1α
HIF-1α has been extensively studied for decades both in vitro and in vivo and it has been 
found that HIF-1α plays a major regulatory role both during development and normal 
physiology as well as in the pathology of a magnitude of different diseases including 
cancers. HIF-1α induces activation of a subset of different genes involved in migration 
and invasion, cell survival and growth, apoptosis, angiogenesis and metabolism. Thus, 
HIF-1α is a key player in many critical aspects of cancer biology.
One hallmark of cancer is increased energy consumption by cancer cells, which 
need increased glucose production and enhanced metabolism. Accumulating evidence 
suggests that HIF-1α is a modulator of metabolic processes by activating genes involved 
in metabolic pathways. HIF-1α is capable of switching oxidative metabolism to 
glycolytic metabolic reactions.   HIF-1α increases glucose metabolism by enhancing 
the expression of Glut 1 and 3, and by enhancing the expression of metabolic enzymes 
such as hexokinases and phosphoglycerate kinase 1. Additionally, HIF-1α masterminds 
metabolic events by enhancing fatty acid synthesis and storage of triglycerides as well as 
reducing fatty acid oxidation. Furthermore, HIF-1α increases nutrition supply to cells by 
promoting angiogenesis. HIF-1α can also enhance metabolism under hypoxic conditions 
by increasing the activity of cytochrome c oxidase, which under low oxygen conditions 
can enhance electron transfer efficiency (Semenza, 2012a; Semenza, 2012b; Huang et 
al., 2014; Semenza, 2014). 
To maintain a normal cell number in tissues, cells proliferate and undergo 
apoptosis, processes in which HIF-1α plays a fundamental role. Importantly, normal 
cell proliferation can be distinguished from abnormal cell growth by changes in the 
balance between proliferation and apoptosis. Neoplastic cells have the capacity to evade 
apoptosis and increase their proliferation rate. Traditionally, HIF-1α has been strongly 
associated with enhanced proliferation and survival of cancer cells by inducing numerous 
genes involved in these cellular events.  HIF-1α induces transcription of a wide range of 
growth factors such as insulin like growth factor, transforming growth factor-α, vascular 
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endothelial growth factor, endothelin and erythropoietin. In addition to these, HIF-1α 
confers immortalizing effects on cancer cells by activating genes involved in telomerase 
maintenance (Semenza, 2012a; Semenza, 2014). Polymerases are a group of enzymes 
participating in the elongation of telomeres in DNA strands, hence, preventing senescent 
cells to enter apoptosis.  In conditions low of oxygen, the transcription of the telomerase 
reverse transcriptase gene is enhanced by HIF-1α, resulting in increased cell proliferation 
(Semenza, 2014).  
In a recent review, a complex trans-regulation between HIF-1α and cell cycle 
regulators has been discussed. HIF-1α has been implicated in regulating the cell cycle 
by affecting cell cycle regulators. Although contradictory to the traditional context that 
HIF-1α is an inducer of proliferation, HIF-1α has been shown to induce cell arrest in 
G1 phase by promoting the activity of p21 and p27, hence decreasing the activity of 
cyclin dependent kinases. On the other hand, cyclin dependent kinase 1 has been shown 
to phosphorylate HIF-1α on serine 668, which leads to activation of HIF-1α even in 
normoxia. This activation results in induction of target genes regulating cell proliferation 
and survival (Ortmann et al., 2014). Furthermore, on the one hand HIF-1α blocks the 
expression of the pro-apoptotic mitochondrial proteins (BAX and BID) and caspases, 
and on the other hand enhances the expression of anti-apoptotic proteins. In both cases 
these responses lead to decreased cell death (Semenza, 2012a). These findings suggest 
that HIF-1α both promotes and blocks proliferation. Thus, the role of HIF-1α in cell 
proliferation needs more studies in order to understand the exact mechanisms underlying 
how HIF-1α accomplishes these tasks. 
HIF-1α has also been implicated in regulating angiogenesis and invasion by 
inducing genes involved in these cellular events. HIF-1α is able to transform cells 
from an epithelial to a mesenchymal phynotype. Both HIF-1α and its target genes have 
been shown to be up-regulated in many types of cancers, highlighting the important 
role and involvement of HIF-1α. Vascular endothelial growth factors (VEGFs), matrix 
metalloproteinases (MMPs), c-myc and RET are all well characterized genes regulating 
cancer cell migration and invasion. These genes have all been shown to be HIF-1α 
target genes. In addition to these, HIF-1α has been shown to activate the genes for lysyl 
oxidases LOX, LOXL1 and LOXL2, which are potent inducers of breast cancer cell 
migration and invasion (Semenza, 2003; Semenza, 2012a; Semenza, 2012b; Semenza, 
2014).
HIF-1α has also been associated with chemoresistance by regulating genes 
involved in this event. The expression of multidrug transporters MDR1 and BCRP, 
which usually pump drugs out of the cell, is enhanced by HIF-1α. In addition, HIF-
1α is capable of conferring resistance to DNA damages induced by chemotherapy 
by inhibiting the action of proteins of crucial importance in these events (Semenza, 
2012a).
These findings verify HIF-1α to have pivotal role in regulating cellular events, 
in particular in cancer cells. The broad role of HIF-1α in cancer has made HIF-1α an 
attractive target for cancer therapy. Thus, several different inhibitors against HIF-1α have 
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been developed. The inhibitors target HIF-1α at the level of transcription, translation and 
activity. Many of these inhibitors have already reached clinical trials, and are tested on 
human patients with great success. 
2.5.2 Classical regulation of HIF-1α
Like many other biological processes, also the HIF-system encounters endogenous 
inhibitors of its own. The main inhibitors are termed prolyl hydroxylases (PHDs) (Srinivas 
et al., 1999; Masson et al., 2001; Masson & Ratcliffe, 2003). However, there are two 
other enzymes involved in the regulation of HIF-1α, namely the acetyltransferase arrest-
defective-1 (ARD1) (Jeong et al., 2002) and the factor inhibiting HIF (FIH) (Hewitson 
et al., 2002).    
The main regulators of HIF-1a are PHDs, which in response to normoxia bind to 
the ODDD of the HIF-1α subunit, and hydroxylate it on proline 402 (Pro402) and 564 
(Pro564). This hydroxylation targets HIF-1α for recognition by the von Hippel Lindau 
complex (pVHL), which polyubiquitinates and finally targets HIF-1α for degradation 
in the proteasome. However, under hypoxic conditions the activity of PHDs is blocked, 
preventing the binding of PHDs to the ODDD of the HIF-1α subunit, and consequently 
the destruction of it. Hence, HIF-1α becomes stabilized by hypoxia (Srinivas et al., 
1999; Tanimoto et al., 2000; Masson et al., 2001; Masson & Ratcliffe, 2003). Upon 
stabilization, HIF-1α is translocated into the nucleus where it binds to its partner HIF-
1β, forming the HIF-1 complex (Kallio et al., 1997). In the nucleus HIF-1 in association 
with co-partners such as CBP/p300 binds to hypoxia response elements (HRE) on a 
variety of different target genes of crucial importance both during normal development 
and in many types of disorders (Lando et al., 2002). The regulation of HIF-1α by PHDs 
is demonstrated in Figure 6.
ARD1 acts independently of oxygen as a facilitator of HIF-1α binding to the 
pVHL. ARD1 is able to acetylate HIF-1α at the Lys532 residue within the ODDD. This 
labeling results in de-stabilization of HIF-1α (Jeong et al., 2002).  The importance of 
Lys532 residue has derived from studies where mutations of the Lys532 residue have 
been shown to stabilize HIF-1α (Tanomoto et al., 2000). 
The recruitment of the co-partner CBP/p300 by HIF-1 involves hydroxylation of 
the asparagine 803-residue (Asn803) in the C-TAD domain of HIF-1α by FIH-1. High 
levels of oxygen can prevent the interaction between HIF-1 and CBP/p300 by blocking 
the activity of FIH-1, ultimately hampering the activation of HIF-1 target genes (Sang et 
al., 2002; Hewitson et al., 2002).    
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Figure 6. Normoxia induces activation of PHDs leading to binding of HIF-1α to pVHL and 
ubiquitination of HIF-1α and subsequent degradation of HIF-1α in the proteasome. Hypoxic 
conditions inhibit PHDs causing translocation of HIF-1α to the nucleus, where HIF-1α binds to 
HIF-1β forming the HIF-1 complex. Thereafter, HIF-1 recruits co-activators and binds to HRE-
elements and activates target genes involved in many different cellular processes. (Adapted from 
Semenza, 2003).
2.5.3 Other modes of regulation of HIF-1α
During the past years, it has become more evident that HIF-1α can also be modulated in 
a non-hypoxic manner by the action of growth factors, cytokines as well as lipids. The 
major mode of regulation has been shown to be at the level of transcription and protein 
synthesis. MAPK and PI3K signaling pathways are the master regulators contributing to 
the enhancement of HIF-1α protein synthesis. Mammalian target of rapamycin (mTOR), 
p70S6K and the translation factor eIF4E are all crucial regulators of protein synthesis, of 
which all are involved in regulating HIF-1α protein synthesis (Semenza, 2003; Zhang et 
al., 2007). In addition, protein kinase C isoforms (PKCs) (Zhang et al., 2007) have been 
proven to be involved in regulating HIF-1α protein expression. 
HIF-1α stability is subject to regulation by heat shock protein 90 (Hsp90) and 
the receptor for activated C kinase 1 (RACK1) in normoxia independently of pVHL. 
Hsp90 is a chaperone involved in protein folding and stabilization during stress and heat 
shock. Binding of HIF-1α to Hsp90 facilitates stability. RACK1 is a scaffolding protein 
with binding ability to a subset of different proteins, and is involved in stabilization of 
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proteins. When HIF-1α binds to RACK1 it is destined for degradation in the proteasome. 
Thus, Hsp90 and RACK1 function as competitors for HIF-1α binding and serve as 
regulator of HIF-1α depending on the circumstances and the preference of HIF-1α for 
these two molecules (Liu et al., 2007).
Moreover, a link between S1P, SK and HIF has emerged during the past few years. 
Initially, Anelli et al. (2008) showed that hypoxia, in fact, increased the expression and 
the activity of SK1, subsequently triggering up-regulation of S1P in U87MG glioma 
cells. The authors reported that inhibition of HIF-2α blocked SK1 and the production 
of S1P, whereas siRNA treatment of HIF-1α resulted in up-regulation of both HIF-2α 
and SK1. These changes in SK1 activity by hypoxia and HIFs correlated with enhanced 
proliferation and migration of glioma cells used in the study. In line with these results, 
Schwalm et al. (2008) was able to show that hypoxia up-regulates the expression and 
activity of SK1, and that HIF-1α and HIF-2α bind to the SK1 promotor region in the SK1 
gene in endothelial cells to enhance migration of these cells.  Furthermore, in vascular 
endothelial and smooth muscle cells, S1P via S1P2 has been demonstrated to increase the 
expression and activity of HIF-1α in a pVHL-independent fashion (Michaud et al., 2009). 
Recently, Salama et al. (2015) demonstrated that in clear cell renal cell carcinoma, which 
is associated with mutations in VHL and increased HIF stability, the expression of SK1 
is elevated. These elevations in the SK1 protein result in high levels of S1P and enhanced 
invasion of these cells. 
2.5.4 HIF-2α 
Although there are many structural and functional similarities between HIF-1α and 
HIF-2α, many studies have indicated that these two transcription factors, in fact, have 
opposing effects and that they activate a different subset of target genes. There are also 
differences in the expression pattern and the mode of activation of these two transcription 
factors. HIF-2α is more prone to become activated even under normoxia for a prolonged 
time, whereas at least normal hypoxic conditions are needed for HIF-1α for activation. 
However, when activated in normoxia, the duration time for HIF-1α activity is rather 
short (reviewed in Zhao et al., 2015b).
In mouse xenograft experiments, tumors originating from lung and colon tissues 
were shown to be exclusively dependent on the activity of HIF-1α for their growth, 
while HIF-2α was found to act as tumor suppressor (Imamura et al., 2009). In line 
with these results, Sun et al. (2013) demonstrated a negative role for HIF-2α in tumor 
growth in hepatocellular carcinoma cells (HCC). In this study, the authors reported 
that HIF-2α induced apoptosis. This apoptotic response of HIF-2α was dependent on 
the action of the transcription factor E2F1, which plays a role in controlling the cell 
cycle by inducing tumor suppressors such as p53. In contrast to these results showing 
an inhibitory effect of HIF-2α on proliferation, in VHL-/- mice the growth of tumors 
developing from kidney and liver were demonstrated to be HIF-2α dependent (Rankin 
et al., 2008). In accordance with the concept of HIF-2α regulating tumor growth and 
invasion, Zhao et al. (2015a) showed that human renal cancer tumorigenesis and 
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invasiveness are dependent on HIF-2α. In a review by Zhao et al. (2015b), several lines 
of evidence implicate HIF-2α as a key regulator of many aspects of tumor progression. 
HIF-2α activates genes important for metabolism, proliferation, angiogenesis and 
metastasis. Thus, HIF-2α might exhibit different effects on cellular events depending 
on the cell type and the genes it activates.
2.5.5 HIF-3α
Among the HIF-family members, HIF-3α is by far the least studied. Therefore, its 
function has remained elusive. There are, however, a few reports dealing with HIF-3α. 
Initially, it was demonstrated by Maynard et al. (2003) that several different splice 
variants of HIF-3α are direct targets for the pVHL ligase complex.  This group even 
identified the proline residues in the ODD domain, and provided evidence that HIF-3α 
is degraded in a pVHL-dependent fashion similar to HIF-1α. Later on, HIF-3α was 
shown to act as an inhibitor of HIF-1α and HIF-2α in clear-cell renal cell carcinoma 
(CC-RCC), thus, suppressing tumor growth and metastasis (Maynard et al., 2007). 
Another report by Ando et al. (2013) is providing insights on different splice variants 
of HIF-3α, where the HIF-3α4 variant acts as a negative regulator of angiogenesis 
in malignant meningiomas. Recently published data has, however, shown that HIF-
3α is also a hypoxia inducible transcription factor inducing genes important for 
cellular function (Zhang et al., 2014b). Thus, more studies are needed to broaden our 
understanding about the role of this transcription factor. However, these few results 
provide exiting insights of HIF-3α, and offer new opportunities for research findings 
and future intervention strategies. 
2.6 Extracellular degrading enzymes
The extracellular matrix (ECM) is a scaffold of several different proteins surrounding 
tissues in an extremely organized way. In order to be able to migrate and invade, cells 
need to have the ECM degraded. The degradation of the basement membrane and the 
extracellular matrix is governed by diverse mechanisms and several factors play major 
roles in this process. The most studied enzymes with the ability to brake down the 
components of the ECM are matrix metalloproteinases (MMP) (Stamenkovic, 2000; 
Sternlicht & Werb, 2001; Löffek et al., 2011; Yadav et al., 2014), lysyl oxidases (LOX) 
(Mayorca-Guiliani & Erler, 2013), urokinase plasminogen activator and its receptor 
(uPA and uPAR) (Noh et al., 2013), matriptase (Miller & List, 2013) and kallikreins 
(Romero Otero et al., 2014). Figure 7 shows the major ECM-degrading enzymes.
The LOX family contains five members termed LOX and LOX-like (LOXL) 
1-4 and they are widely distributed in the tissues. LOX is secreted as zymogen and 
activated through cleavage of the glycosylated N-terminal domain of LOX by bone 
morphogenetic protein 1 (BMP1). LOX functions as a collagen and elastin cross-
linker, hence, modifying the extracellular matrix. As LOX is a HIF target gene and 
often up-regulated by hypoxic conditions, it has gained a substantial amount of interest 
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in the tumor biology filed. LOXs have been implicated in a variety of different cellular 
responses, including migration, invasion and angiogenesis (Mayorca-Guiliani & Erler, 
2013). 
Kallikreins are secreted serine proteases widely expressed in the tissues. The 
human kallikrein family comprises of 15 members, representing up to date the largest 
serine protease family. Kallikreins are synthesized as prekallikreins, which need to be 
activated in order to be able to exert their effects on the ECM. The activation of kallikreins 
is facilitated by factor XII. This same enzyme is also able to generate plasmin from 
plasminogen.  The main function of kallikreins is to cleave kininogen to release kallidin. 
Kallikreins are implicated in several physiological and pathophysiological conditions. 
They are involved in regulating blood pressure, vascular cell growth and smooth muscle 
contraction. Kallikreins are also involved in neurodegenerative diseases. Nonetheless, 
kallikreins have also been linked to cancers including ovarian and prostate cancer. Due 
to their wide expression pattern, kallikreins function as biomarkers for prostate cancer 
(Romero Otero et al., 2014).
The uPA receptor is a glycosylphosphatidylinositol (GPI)-anchored protein linked 
to the plasma membrane. The binding of pro-uPA to uPAR results in cleavage of plasmin 
from plasminogen. Plasmin is able to activate MMPs, a response leading to degradation 
of ECM. In cancers, the uPA-uPAR system has been shown to be up-regulated and play 
a fundamental role in regulating many central processes important in the progression 
of cancers. It is well documented that uPAR is also a HIF-1α target gene. Hence, uPAR 
is up-regulated in hypoxia and modulates cancer cell proliferation, growth, migration 
and invasion. uPAR is able to interact with other receptor systems, for example growth 
factor receptors as well as integrin receptors, which all elicit important roles in invasion 
and metastasis. Thus, inhibition of uPA-uPAR has been of great interest in treatment of 
cancer patients (Noh et al., 2013).
Matriptase is a type II transmembrane protease that activates the GPI-anchored 
prostatin, which initiates a proteolytic cascade important for the degradation of ECM. 
Similar to many other biological systems, the matriptase-prostatin system has its own 
endogenous inhibitor, namely hepatocyte growth factor activator inhibitor-1 (HAI-1). 
The activation of matriptase encounters sequential cleavages and close collaboration 
with its inhibitor. In fact, many studies have shown that matriptase is co-expressed with 
HAI-1. Known in vivo substrates of matriptase include hepatocyte growth factor (HGF) 
and prostatin, while in vitro matriptase cleaves uPA, the G-protein-coupled protease 
activated receptor-2 (PAR2), the platelet-derived growth factor-D (PDGF-D) and the 
human acid-sensing ion channel 1.  Abnormalities in matriptase activity have been liked 
to several diseases including human autosomal recessive icthyosis with hypotrichosis 
(ARIH), Netherton’s syndrome and cancers.  Recently, matriptase has emerged as a 
potential oncogene playing a central role in cancer progression. It has been found to be 
up-regulated in many types of cancers governing many central events occurring during 
proliferation and migration (Miller & List, 2013).
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Figure 7. Demonstration of several different ECM-degrading enzymes of crucial importance for 
migration and invasion of cancer cells.  
2.6.1 Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are zinc dependent proteolytic enzymes involved 
in the degradation of the extracellular matrix. The MMP family is huge and is 
divided into several subgroups depending on their function and localization (shown 
in Figure 8). Up to date 26 members of MMP family have been characterized in 
humans. MMPs can be secreted into the extracellular milieu, be membrane bound 
via a GPI-anchor or reside in the plasma membrane as transmembrane proteins. The 
MMP family consists of gelatinases, metalloelastases, enamelysins, membrane-type 
MMPs, collagenases, stromelysins, tissue inhibitors and others. In the upcoming 
sections only the gelatinases and MT1-MMP will be described. A brief description of 
TIMPs will also be provided (Stamenkovic, 2000; Sternlicht & Werb, 2001; Löffek et 
al., 2011; Yadav et al., 2014).   
The structure of MMPs is conserved between different members of the MMP 
family, and they share common domains. There are three main domains: the pro-peptide 
domain, the catalytic domain, and the haemopexin-like C-terminal domain. MMPs 
are synthesized as zymogens with a pro-peptide. Upon activation the pro-peptide is 
cleaved resulting in a shift towards a smaller molecular weight of the entire protein. The 
catalytic domain has a conserved sequence, where zinc ions can bind. Thus, this domain 
is the catalytically active domain. The haemopexin-like C-terminal domain is used for 
interaction with other proteins (Stamenkovic, 2000; Sternlicht & Werb, 2001; Löffek et 
al., 2011; Yadav et al., 2014).
Due to their ability to cleave a wide spectrum of substrates, MMPs have been 
found to have profound and essential roles in many physiological and pathophysiological 
processes. Thus, they regulate events during tissue remodeling and bone growth and they 
take crucial part in angiogenesis and vascular development. MMPs are also involved 
in immune response, wound healing as well as migration. Interestingly, MMPs have 
been shown to perform apoptotic actions as well by cleaving FAS ligand and activating 
TGF-β. In contrast to that, overproduction of MMPs induces tumor progression and 
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metastasis (Stamenkovic, 2000; Sternlicht & Werb, 2001; Löffek et al., 2011; Yadav et 
al., 2014; Itoh 2015). 
Figure 8. Presentation of the MMP family. The gelatinases MMP2 and MMP9, which were 
studied in detail in this thesis, are placed in the center. (Adapted and modified from https://upload.
wikimedia.org/wikipedia/commons/2/22/Matrix_Metalloproteinases.png)
2.6.2 Regulation of MMPs
Decades of studies and substantial amount of evidence have established new research 
strategies and broadened our understanding of the connection between carcinogenesis 
and MMPs. In fact, MMPs have been demonstrated to be altered and to play major 
roles in several types of cancers (Stamenkovic, 2000). Therefore, understanding the 
mechanistic regulations of these endopeptidases is of crucial importance in establishing 
new therapeutic interventions. 
MMPs are regulated at the level of gene transcription, extracellular localization 
and compartmentalization, proenzyme activation, as well as by inhibition of enzymatic 
activity. In respect to gene regulation, MMPs are regulated by a variety of different 
means. Transcriptional and post-translational regulations by growth factors, cytokines, 
micro-RNA (miRNA), as well as direct binding to the AP-1 binding site in the promoter 
region of the MMP gene are the most common mechanisms of regulation (Stamenkovic, 
2000; Löffek et al., 2011; Yadav et al., 2014).
As most MMPs are secreted into the extracellular space, the catalytic activity 
of these is already determined by their localization in the tissue. The activation of the 
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proenzyme requires removal of the pro-peptide. The removal of the pro-peptide is 
achieved by direct removal by the aid of other endo-peptidases, conformational changes 
in the pro-domain or by chemical alternations (Löffek et al., 2011; Yadav et al., 2014).
Within the MMP family a subgroup of four members exist. These are termed 
tissue inhibitors of matrix metalloproteinases (TIMPs). TIMPs function as endogenous 
inhibitors of MMPs. Additionally, α2-macroglobulin the broad-spectrum inhibitor of 
proteinases, has been implicated in inhibiting MMPs. The inhibition of MMPs requires 
interactions between the endogenous inhibitors and activators. This is well documented 
for activation of MMP2 by TIMP2 and MT1-MMP (Löffek et al., 2011; Yadav et al., 
2014). 
2.6.3 MT1-MMP
Membrane-type MMPs are a subfamily of MMPs consistent of 6 members, of which MT1-
MMP (also called MMP14) is the most studied and quite well understood. Membrane-
type MMPs reside in the plasma membrane, of which some are transmembrane proteins, 
while a couple of them are connected to the plasma membrane via a GPI-anchor. MT1-
MMP is widely expressed in several different tissues. Nonetheless, it is overexpressed 
in many types of cancer cells and its functions were therefore mainly discovered in 
cancer cells. It participates in proteolysing a wide range of ECM components, including 
collagen (Itoh, 2015). MT1-MMP is a key player in migration and invasion. Thus, due 
to these particular functions it has gained a substantial amount of interest. In respect to 
cancers, MT1-MMP is responsible for many aspects characteristic for tumor progression 
ranging from simple cell motility to deadly metastatic features. MT1-MMP is a crucial 
component of several membrane structures involved in cell motility and migration such 
as focal adhesions, filopodia, lamellipodia, invadopodia and pseudopodia. In these 
structures MT1-MMP associates with proteins important for migration such as focal 
adhesion kinase and Rac1 (Itoh, 2015).  Nonetheless, MT1-MMP can also promote 
carcinogenesis by a non-proteolytic mechanism. It has been demonstrated to modulate 
the expression and activity of several proteins regulating cell motility and invasion 
such as HIF, Notch and Rho-A. Due to its broad involvement in tumorigenesis, MT1-
MMP has become one of the most targeted ECM-degrading enzymes in the treatment of 
cancers, and it is an extremely attractive molecule for future therapeutic interventions 
(Itoh, 2015).  
2.6.4 Gelatinases: MMP2 and MMP9
Matrix metalloproteinases 2 and 9 are secreted into the extracellular space. They are 
called gelatinases due to their ability to use gelatin as substrate. MMP2 and MMP9 
are among the most widely distributed MMPs and are involved in the breakdown of 
collagen IV. Gelatinases participate in a subset of different cellular functions including 
proliferation, survival, angiogenesis as well as migration and invasion (Stamenkovic 
2000; Sternlicht & Werb 2001; Löffek et al., 2011; Yadav et al., 2014). Although 
secreted into the extracellular space, MMP2 is known to interact with other membrane 
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proteins such as integrins (α4β3) in the outer leaflet of the membrane, and degrade the 
extracellular matrix without any need for secretion.  Similarly, it has been suggested that 
MMP2 can interact with its activator, MT1-MMP in the membrane, thereby regulating 
invasion (Sternlicht & Werb, 2001; Mitra et al., 2003).
2.6.5 Sphingolipids and MMPs
There is a substantial amount of evidence from in vitro studies suggesting that S1P can 
regulate MMP2 and MMP9 both in normal and cancer cells. In endothelial cells, S1P 
has been suggested to induce MMP2 and VEGF via the transcription factor ZNF580 
promoting proliferation, migration and angiogenesis of the cells  (Sun et al., 2010). 
Moreover, Chang et al. (2013) demonstrated that S1P enhances the expression of 
VEGF-C via a MMP2 and FGF-dependent signaling pathway in human umbilical vein 
endothelial (HUVEC) cells.  Furthermore, in ovarian cancer cells S1P enhances invasion 
by activating MMP2 through Gi and Rac1 (Devine et al., 2008). In breast cancer 
MCF10A cells, S1P induces secretion of MMP9 and migration via S1P3 and Gq (Kim et 
al., 2011). In accordance with these results, the invasion of head and neck squamous cell 
carcinomas has been associated with enhanced activity of SK1, MMP2 and MMP9 as 
well as activation of the ERK1/2 and /AKT pathway (Tamashiro et al., 2014).
Many previous reports have elucidated a role for S1P and also lysophosphatidic 
acid (LPA) in MT1-MMP regulation and the importance of MT1-MMP in migration 
and invasion (Gingras et al., 2008, Sun et al., 2010, Wu et al., 2005, Annabi et al., 2009; 
Devine et al., 2008). Interesting results have shown that in hepatocellular carcinoma 
cells lysophosphatidic acid (LPA) induces invasion by activating MMP9 (Lou et al., 
2013). Furthermore, LPA induces invasion of MCF-7 cells, which is mediated by RhoA, 
ROCK, MMP2 and MMP9 (Sun et al., 2015). Annabi et al., (2009) showed that S1P 
increases MMP2 activity and migration of CD133(+) glioblastoma stem cells, and that 
siRNA knock down of MT1-MMP abolishes S1P-induced cell migration. 
Thus, accumulating evidence suggests that there is a connection between 
sphingolipids and MMPs of essential importance in progression of cancers. Due to 
characteristic features of S1P and MMPs, inhibition of S1P receptors could indeed be 
beneficial for cancer patients.
2.6.6 Calpain 
Calpains are a widely expressed family of intracellular calcium-dependent proteolytic 
enzymes responsible for the cleavage of a wide range of different proteins. The calpain family 
consists of 15 members, however, calpain 1 and 2 (mu-calpain and m-calpain respectively) 
are the most thoroughly studied. As many other proteins, calpains also encounter their own 
endogenous inhibitor termed calpastatin.  Calpains have been implicated in several central 
events both during development and in many diseases, including many types of cancers. 
Giving the nature of cancer cell properties, calpains have been linked to all features and 
events of cancer cell transformation due to their wide spectrum of substrates (Franco & 
Huttenlocher, 2005; Leloup & Wells, 2011; Moretti et al., 2014). 
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First identified by Carraghare and coworkers, calpains were shown to be involved 
in cell transformation due to the fact that their expression and activity was induced by 
v-Src, v-Myc, k-Ras,v-Fos and v-Jun (Carragher et al., 2002; Carragher et al., 2004). 
Likewise, Niapour et al. (2008) showed that c-Myc activates calpains by suppressing their 
inhibitor calpastatin. Thus, all these events highlight the role of calpains in malignant 
transformation. 
Calpains are known to have a central role in regulating motility, migration and 
invasion of cancer cells by enhancing the expression and activity of a wide range of 
different proteins important for these processes. In respect to motility, both calpain 1 and 
calpain 2 play a central role. Calpain 1 is important for the formation of focal adhesion 
complexes in the front of the cell, while in the rare of the cell calpain 2 is essential 
for the disassembly of the complexes, hence, for cell retraction (Glading et al., 2002). 
Furthermore, calpains have been implicated in modulating migration by proteolysing 
the tumor suppressor E-cadherin, thereby facilitating migration of prostate cancer cells 
(Rios-Doria et al., 2003). In addition, calpains have been well established in regulating 
invasion by modulating the expression, secretion and activity of MMPs in several types 
of cancer cells. Chen et al. (2013) showed that in hepatocellular carcinoma cells siRNA 
silencing of calpain 1 and 2 resulted in a decrease of both MMP2 and MMP9 secretion, 
which reflected the invasive phenotype of these cells. Furthermore, the migration and 
invasion of lung cancer cells have been linked to increased calpain activity and MMP9 
expression (Meng et al., 2009). Jang and co-workers (2010) reported that the invasion of 
glioblastoma cells was shown to be dependent on calpain 2 and MMP2.  Likewise, the 
invasion of osteosarcoma cells was suggested to be dependent on calpain 1 and 2 and 
MMP2 (Fan et al., 2009). Furthermore, the invasion of T-antigen-immortalized mouse 
embryonic fibroblasts cells into matrigel has been shown to be dependent on calpain and 
MMP2 expression (Postovit et al., 2002). In addition to these results, calpains have been 
implicated in regulation of cellular processes by modulating MT1-MMP. Endothelial 
sprout formation and invasion have been shown to be dependent on calpain and MT1-
MMP in 3D collagen matrices (Kang et al., 2011; Kwak et al., 2012). Thus, all these 
data in the literature highlight the broad spectrum of regulation of cellular processes by 
calpains, and the down-stream signaling pathways they activate to achieve their tasks. 
2.7 Studies related to thyroid cancer
2.7.1 MMPs and HIF in thyroid cancer
A growing body of evidence about HIF and MMPs suggests that they have a role in 
thyroid cancer. Several previous studies have shown that an increased expression and 
activity of both MMP2 and MMP9 correlate with an enhanced invasion of thyroid cancer 
cells (Rajoria et al., 2011; Zhang et al., 2012: Yang et al., 2013). Moreover, MT1-MMP 
has also been associated with an invasive phenotype of thyroid cancer cells (De Amicis 
et al., 2013). Burrows et al. (2010) demonstrated that in normal thyroid tissues HIF-1α is 
barely detectable. However, the authors were able to detect high amounts of HIF-1α in 
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different types of thyroid cancer cells, correlating with high grade of invasiveness. The 
highly expressed HIF-1α protein correlated with the activity of PI3K and RAF/MEK/
ERK1/2 signaling pathways.  A role of HIF-1 α and MMP9 is also evident in papillary 
K1 thyroid cancer cells. Tan and co-workers (2014) showed that curcumin has anti-
migratory effects on K1 cells. This response was due to the ability of curcumin to decrease 
the mRNA and protein levels of HIF-1α as well as attenuate the binding capacity of HIF-
1α to the HRE-elements on target genes. In addition, curcumin inhibited the expression 
of MMP9, resulting in inhibition of migration of the cells.  Two parallel studies by 
Wang and collaborators (2013a; 2013b) demonstrated that high expression of HIF-1α 
and HIF-2α in papillary thyroid cancer cells is highly associated with advanced TNM 
stage, reflecting the involvement of HIF-1α/2α in thyroid malignancies. Furthermore, 
Rajora et al. (2014) could show a link between estrogen and HIF in HUVEC cells, in 
a way that HIF-1α inhibition was able to attenuate estrogen-induced migration of these 
cells. Collectively, a role for HIF and MMPs in thyroid cancer progression is emerging, 
which is of great importance considering the future medical interventions. 
2.7.2 S1P in thyroid cancer
The significance of S1P and its receptors for thyroid cancer proliferation and migration 
has been one of the milestones of Törnquist laboratory. In previous studies from 
Törnquist laboratory, follicular ML-1 and FTC-133 cells as well as the anaplastic C643 
and THJ-16T cells were used. The receptors dominating in ML-1 and FTC-133 cells are 
S1P1,3, and the main receptor regulating cell function in C643 is S1P2. Not surprisingly 
and as can be expected, S1P acts as a potent inducer of migration and invasion of ML-1 
and FTC-133 cells (Balthasar et al., 2006; Balthasar et al., 2008; Bergelin et al., 2009; 
Bergelin et al., 2010; Törnquist 2013), whereas the migration of C643 and THJ-16T 
cells is blocked by S1P (Asghar et al., 2012). These differences in the S1P response 
highlight the importance of receptor expression profile and the ultimate response of 
S1P being exclusively dependent of the receptors present in the cells.  The existence of 
communication between the S1P receptor system and the receptors for growth factors is 
well established. In line with this concept, it was demonstrated that a complex crosstalk 
between S1P receptors and vascular endothelial growth factor receptor 2 (VEGFR2) 
exists. VEGF can modulate S1P receptors and SK1 activity, and S1P is simultaneously 
able to influence the expression and activity of VEGFR2 as well as the secretion of 
VEGF-A. Furthermore, it was demonstrated that PI3K, ERK1/2, PKCα are important 
intermediates of this interplay, which subsequently leads to enhanced migration of ML-1 
cells (Balthasar et al. 2008; Bergelin et al., 2009; Bergelin et al. 2010). In addition to these 
findings, the Törnquist laboratory has also been able to present a link between SK1 and 
VEGFR2 in thyroid cancer. SK1 (Guan et al., 2001) and VEGFR2 (Turner et al., 2003; 
Kim et al., 2006) have been shown to be up-regulated in thyroid cancers, associated 
with a high grade of invasiveness. Thus, accumulating evidence suggests that S1P and 
VEGFR2 are emerging as potent regulators of thyroid cancer cell migration and invasion. 
S1P and SK1 have also been shown to play key roles in calcium signaling in thyroid 
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cancer. S1P is able to modulate calcium channels and signaling events downstream from 
the channels important for proliferation and migration (Törnquist, 2012).
2.7.3 Treatment of thyroid cancer and challenges
The overall prognosis for some types of thyroid cancers is relatively good and favorable 
when the diagnosis is carried out early enough at a proper stage of the disease. Currently, 
there are several types of treatments for thyroid cancers. The methods, however, are, 
as for any other type of cancer, highly traditional and unspecific (Schneider & Chen, 
2013; Jin et al., 2013). Normally, partial or total thyroidectomy is carried out followed 
by radiation and chemotherapy. However, the method of treatment should be chosen 
with accurate consideration depending on the type of the cancer and the stage of the 
tumor. One of the hallmarks of thyroid cancer is the recurrence of the disease after the 
first line of treatment. Recurrences can occur both locally at the site of the original 
tumor, however, metastases can also emerge leading to management difficulties in 
the second line of treatment (Schneider & Chen, 2013; Jin et al., 2013). The currently 
available chemical inhibitors used for thyroid cancer treatment are inhibitors of the 
genes altered in these groups of diseases. Often, the inhibitors target MAPK/ERK and 
VEGFR2, influencing cellular growth and metastasis. Nevertheless, these inhibitors 
are shown to be ineffective, highlighting the importance of more efficient, specific 
and targeted drugs, increasing the survival of the patients (Jin et al., 2013; Perri et al., 
2014). 
As S1P is a potent inducer of thyroid cancer cell migration and invasion, S1P-
receptors and SK1 could serve as good and attractive candidates for cancer therapy. 
In fact, targeting these has been proven to be beneficial in clinical trials. Currently, 
there are several S1P-receptor modulating drugs in advance phases of clinical trials. 
The pharmaceuticals are aimed to target S1P1,3 to block invasion, angiogenesis and 
proliferation of cancer cells. At the same time, molecules that enhance S1P2 function 
are acquiring increased attention. Thus, activation of S1P2, which normally is an anti-
migratory receptor, might be beneficial for cancer patients (Zu Heringdorf et al., 2013) 
2.7.4 FTY720, S1P-receptor modulating drug
Fingolimod (FTY720) is an immunosuppressive drug approved by FDA and EMA for 
treatment of multiple sclerosis (MS). FTY720 inhibits egress of lymphocytes from 
lymph nodes by inhibiting S1P1, thus preventing the migration of immune cells to the 
brain. Due to these actions, FTY720 is used in the treatment of MS (Matloubian et al., 
2004; Lo et al., 2005; Chung & Hartung, 2010; Bigaud et al., 2014; Kim et al., 2015). 
It is an agonist for all S1P-receptors except for S1P2. However, it has highest affinity 
for S1P1, but affects also S1P3 very strongly. Exogenous FTY720 is taken up by cells 
and is phosphorylated by SK2 (Paugh et al., 2003), after which p-FTY720 is secreted by 
cells into the extracellular space, where it binds to S1P-receptors. The inhibitory effect 
of FTY720 on S1P-receptors is due to its ability to internalize the receptors, and cause 
degradation of S1P-receptors in the proteasome (Oo et al., 2007).
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In addition to its immunosuppressive effects, FTY720 displays promising effects 
on cancer cell migration and proliferation as it has been shown to act as an inhibitor 
of SK1.  FTY720 has also been shown to inhibit proliferation of a variety of different 
cancer cells by triggering G1 arrest and up-regulating p21 and p27. Furthermore, the 
anti-proliferative effect of FTY720 is due to its ability to increase the expression of 
PTEN, and to subsequently inhibit AKT. Moreover, FTY720 has the capacity to block 
the mouse double minute 2 homolog (MDM2), which is an E3 ubiquitin ligase and a 
negative regulator of p53. Therefore, as can be expected, FTY720 enhances the stability 
of p53 causing increased apoptosis and decreased growth. Furthermore, FTY720 has the 
ability to induce activation of caspase-3 and subsequently apoptosis. In addition to its 
anti-proliferative effects, FTY720 displays anti-migratory capacities as well. FTY720 
achieves this by inhibiting integrins and activating RhoA (Pyne & Pyne, 2013, Kunkel 
et al., 2013 and Selvam & Ogretmen, 2013; Alshaker, 2013). Thus, FTY720 has a broad 
spectrum of effects on cancer cells.
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3. AIMS
The role of sphingolipids in thyroid cancer has remained poorly understood. Previous 
investigations by our group, however, demonstrated that S1P very potently induces 
migration of thyroid follicular ML-1 cancer cells via S1P1,3 and Gi/0 (Balthasar et al., 
2006). Moreover, we showed that S1P receptors crosstalk with VEGFR2, which is 
of crucial importance for ML-1 cell migration. The aim of this study was to further 
investigate the mechanisms underlying the S1P-evoked migration and invasion of ML-1 
cells. For this purpose we studied specifically:
1. The significance of HIF-1α for S1P-induced migration of thyroid cancer cells.
2. The role of MMP2 and MMP9 in S1P-evoked invasion of thyroid cancer cells.
3. The effect of the S1P-receptor modulator Fingolimod (FTY720) on the proliferation 
and invasion of thyroid cancer cells.
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4. MATERIALS AND METHODS
4.1 Cell lines
In this project several thyroid cell lines were used, which were cultured according to Table 
1 and maintained in a humidified incubator at 37C˚ and under 5% CO2. For experiments in 
hypoxia, cells were grown in a hypoxia workstation with 1% oxygen at 37 ˚C.
Table 1. The maintenance and the composition of culture medium for different cell lines.
Cells Medium
ML-1 (I, II, III) and C643 
cells (III)
Cultured in DMEM (Dulbecco´s modified Eagle’s medium) 
supplemented with 2 mM L-glutamine, 10% FCS and 100 U/ml 
penicillin-streptomycin
FTC-133 cells (I, II, III) Grown in DMEM + Ham’s F12 medium (1:1) supplemented with 
10% FCS and 2 mM L-glutamine
Nthy-ori 3-1 CELLS (III) Cultured in RPMI 1640 medium supplemented with 2 mM 
Glutamine, 10% FBS, and 1% penicillin/streptomycin
4.2 Whole cell lysates (I, II, III)
After being treated as indicated, cells were washed with ice-cold PBS, and lysed in 
lysis buffer (10 mM Tris pH 7.7, 150 mM NaCl, 7 mM EDTA, 0.5% NP-40, 0.2 mM 
PMSF, 0.5 μg/ml leupeptin). Cell lysates were centrifuged at 13 000 rpm for 15 min 
at 4°C, whereafter pellets were removed and supernatants were collected. Protein 
concentrations were determined with the BCA Protein Assay kit (bicinchoninic acid), 
thereafter Laemmli sample buffer (LSB) was added and the lysates were boiled to be 
used for PAGE-analyses.  
4.3 Immunoprecipitation (I)
Cells were treated as indicated and lysed with IP lysis buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 0.1% NP-40, 0.2 mM PMSF, 0.5 μg/ml leupeptin). Protein concentrations 
were determined as described earlier, and lysates with equal protein concentrations and 
volumes were pre-cleaned with 20 μl of Protein A/G PLUS-agarose beads for 1 h at 4°C. 
Pre-cleaned lysates were incubated with 2 μg of antibody or IgG control overnight at 4°C 
followed by incubation with 40 μl of Protein A/G PLUS-agarose beads for 2 h at 4°C. 
Thereafter, lysates were centrifuged at 13 000 rpm for 2 min at 4°C. After discarding the 
supernatants, the agarose beads were washed with IP washing buffer (50 mM Tris-HCl 
pH 7.5, 250 mM NaCl, 0.1% NP-40), and Laemmli sample buffer (LSB) was added, the 
samples were boiled and run on SDS-PAGE. 
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4.4 SDS-PAGE and western blotting (I, II, III) 
Equal amounts of protein were loaded on SDS-PAGE gradient gel (8-12% polyacrylamide) 
and later proteins were transferred onto a nitrocellulose membrane by electrophoresis. 
Thereafter, membranes were blocked with 5% milk in TBST (Tris-buffered saline 
(NaCl, 150 mM; Tris-base, 20 mM (pH 7.5)) containing 0.1% Tween 20 for 1 h at 
room temperature followed by incubation in primary antibody overnight at 4°C and 
in horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. 
Proteins were detected by incubating membranes with Plus ECL solution. Protein bands 
were analyzed with the ImageJ program. As a loading control Hsc70 or β-actin was 
used and target protein densitometry was normalized with the loading control. Protein 
amounts in collected medium were normalized to total protein concentrations in 
respective samples.  
4.5 Cell migration (I, II, III) 
One day prior to the experiment the upper surface of Transwell inserts (6.5 mm-
diameter and 8 µm pore size) were coated with 5 µg/cm2 human type IV collagen. 
Cells were serum-starved overnight. At the day of the experiments, the inserts were 
reconstituted with medium and the cells were treated with inhibitors as indicated. After 
being detached, 200 000 cells in serum-free medium were added into the upper wells 
of the inserts. Chemoattractants were added into the lower wells. The inhibitors were 
added to both wells. The cells were allowed to migrate as indicated. After removing the 
un-migrated cells from the upper surface of the membrane with a cotton swab, migrated 
cells were fixed with 2% paraformaldehyde in PBS for 10 min and stained with 0.1% 
crystal violet in 20% methanol for 5 min. Thereafter, migrated cells were counted in a 
light microscope.  
4.6 Transfection with siRNA (I, II) 
Cells were transfected with siRNA or plasmids with either the N-TER, HiPerfect 
transfection reagents or by electroporation with Amaxa Cell Line Optimization 
Nucleofector Kit and Amaxa electroporation device according to the manufacturer’s 
instruction. Transfected cells were plated for 24 h and serum starved for another 24 h. 
Then, cells were treated and the experiments were carried out as indicated. 
4.7 RNA extraction and reverse transcriptase PCR (I)
For extraction of total RNA the Aurum Total RNA Mini kit was used and RNA 
concentrations were determined using the RiboGreen RNA Quantitation Reagent 
according to the manufacturer’s instructions. Thereafter, Reverse transcriptase PCR was 
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performed with SuperScript III Reverse Transcriptase to produce cDNA according to the 
manufacturer’s instructions. 
4.8 Quantitative real-time PCR (I)
 The quantitative PCR assays were designed using the Universal ProbeLibrary Assay 
Design Center (www.roche-applied-science.com). Reaction mixtures were prepared 
with ABsolute QPCR Rox Mix or with the KAPA Probe Fast qPCR Kit and real-time 
quantitative PCR was performed using the Applied Biosystems 7900HT Fast Sequence 
Detection System or the StepOnePlus Real-Time PCR system. The amplification results 
were analyzed with the SDS and RQ Manager programs. GAPDH and HPRT1 were used 
as reference genes.
4.9 Luciferase assay (I)
To determine the luciferase activity of HIF-1 cells were co-transfected with either TK-
Luc and Ubi-Renilla plasmid or HRE-Luc and Ubi-Renilla plasmid by electroporation 
with an Amaxa nucleofector device. Cells were lipid-starved 24 h after transfection, 
and the next day treated as indicated. Luminescence was measured with the DualGlo 
Luciferase Assay System according to the manufacturer’s instructions. Renilla luciferase 
luminescence was used to normalize Firefly luciferase luminescence. 
4.10 Zymography (II, III)
Cells were treated as indicated, medium was collected and equal volumes of sample 
medium were mixed with loading buffer (0.1 M Tris-phasphate buffer (pH 6.8) containing 
20 % glycerol, 6 % SDS, 0.04 % bromphenol blue), and electrophoresed on 10% (SDS)-
polyacrylamide gels containing 1mg/ml gelatin. First, gels were incubated in zymo 
buffer I for 30 min. Thereafter, gels were incubated for 30 min in the zymo buffer II. To 
allow gelatinolytic activity gels were incubated in zymo buffer III overnight at 37 °C. 
Then the gels were stained with Coomassie Brilliant Blue R250 for 1-2 h, and de-stained 
for 1-2h. Gelatinolytic activity was quantified by the ImageJ software. The data was 
normalized with the respective total protein concentrations of the samples. 
Table 2. The composition of zymo buffers.
Buffer Composition
zymo buffer I 50 mM Tris-HCl containing 2.5 % Tween 80 and 0.02 NaN3 (pH 7.5)
zymo buffer II 50 mM Tris-HCl containing 2.5 % Tween 80 and 0.02 NaN3, 1 µM ZnCl2 and 5 mM CaCl2 (pH 7.5)
zymo buffer III 50 mM Tris-HCl, 5 mM CaCl2, 1 µM ZnCl2 and 0.02% NaN3 (pH 7.5)
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4.11 Calpain activity assay (II)
The activity of calpains was determined using a calpain activity assay according to the 
manufacturer’s instructions. Two million cells were plated on 10 cm plates and treated 
with 100 nM S1P for the indicated times. Then, cells were harvested and lysed, and 
protein concentrations were determined as described earlier. The fluorometric readings 
were measured using a Victor fluorescence analyzer at excitation of 400 and emission of 
505 nm, directly proportional to calpain activity and the values were normalized with the 
respective total protein concentrations in the plates. 
4.12 Proliferation assay (I, II, III)
4.12.1 Cell Titer
Totally, 10 000 cells/well were plated on 96-well plates and serum starved for 24 h 
prior to treatment. Thereafter cells were treated as indicated and the experiments were 
terminated by using CellTiter® cell proliferation assay kit according to the manufacturer’s 
instructions. The colorimetric reactions were measured by reading absorbance at an 
excitation of 492 nm and emission at 505 nm using a Victor fluorescence analyzer. 
4.12.2 3H-thymidine incorporation assay (I, III)
To further measure the proliferation, 3H-thymidine incorporation assay was performed. 
For the assay 75,000 cells were cultured for 24 h on 35 mm plates and serum starved for 24 
h. Thereafter, cells were treated as indicated, followed by incubation with 3H-thymidine 
(0.4 µCi/ml) for at least 4 h. Then, the cells were washed with ice cold PBS. After that 
the cells were incubated with 5% trichloroacetic acid for 10 min followed by incubation 
with 0.1 N NaOH for another 10 min. The radioactivity directly proportional to cell 
proliferation was measured by using a Wallac 1410 liquid scintillation counter. 
4.13 Fluorescence-activated cell sorting
For the assay, cells were grown in 10 cm plates, and complete medium was changed to 
SFM overnight. The cells were then treated as indicated, washed with ice-cold PBS and 
detached. Next, 500 000 cells were suspended and incubated in propidium iodide (PI) 
solution (0.05 mg/ml PI, 3.8 μM sodium citrate and 0.1% Triton-X-100 in PBS) for 15 
min at room temperature. Analyses of the samples were performed by flow cytometry 
using ModFit LT 4.1 software (Verity Software House Inc., Topsham, ME, USA)
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5. RESULTS AND DISCUSSION
5.1 HIF-1α participates in S1P-evoked migration (I)
5.1.1 S1P induces HIF-1α expression and activity 
The role of S1P in regulating migration of ML-1 follicular thyroid cancer cells had 
previously been thoroughly investigated by our group, and it was known that S1P 
strongly induces migration of these cells via S1P1,3 and Gi/0  proteins (Balthasar et al., 
2006). Furthermore, HIF-1α was shown to be a potent inducer of cancer cell migration 
and tumor growth as well as angiogenesis (Semenza, 2003; Semenza, 2010). These facts 
suggested that HIF-1α might be involved in S1P-induced migration of thyroid cancer 
cells. It turned out that S1P up-regulated HIF-1α protein expression in a time- and 
concentration dependent fashion under normoxic conditions in both ML-1 and FTC-133 
cells. In addition, the expression of HIF-1α in hypoxia was studied, and results showed 
a substantial increase of HIF-1α protein expression in ML-1 cells. The effect of S1P on 
HIF-1α activity was also studied, and S1P was able to increase the activity of the HIF-
1. To find out target genes, siRNA against some known classical HIF-1-target genes 
of importance for migration was used. It was found that S1P-induced gene expression 
of VEGF-A (vascular endothelial growth factor), AMF (autocrine motility factor) and 
TGFα (transforming growth factor) (Semenza, 2003) was abolished when HIF-1 gene 
was silenced by siRNA, indicating that these are HIF-1α target genes in ML-1 cells. As 
it was shown that S1P enhanced HIF-1α, it was of interest to find out the mediators of 
this response. For this purpose some signaling intermediates known to be of importance 
for S1P-signaling in ML-1 cells and also in regulating HIF-1α were investigated. It was 
found that S1P enhanced HIF-1α via S1P3, Gi/0 and the downstream effectors MEK, 
PI3K and PKCβI and mTOR in ML-1 cells. In contrast, PKCα did not participate in the 
S1P-evoked regulation of HIF-1α expression. Collectively, S1P enhanced the expression 
and activity of HIF-1α via PKCβI, PI3K, ERK1/2, and induced genes important for 
migration.
5.1.2 S1P increases translation and stability of HIF-1α
Since S1P enhanced the protein expression of HIF-1α, it was of interest to figure out 
if S1P achieved this by inducing transcription. However, it was observed that the 
S1P-induced HIF-1α protein is not due to enhanced transcription, which raised the 
speculation that S1P might affect the translation or stability of HIF-1α. According to 
Semenza (2003) HIF-1α protein synthesis is regulated by p70S6K and eIF4E, therefor, 
it was interesting to find out if S1P was increasing the synthesis of HIF-1α protein. 
As expected, S1P phosphorylated eIF-4E on Ser209, 4EBP1 on Ser65 and p70S6K on 
Thr389, and inhibition of these could abolish the S1P-evoked increase in HIF-1α protein 
levels, meaning that S1P induced protein synthesis of HIF-1α in ML-1 cells. The same 
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kinds of responses were also observed in FTC-133 cells. These results were in line with 
previously published data (Zhang et al., 2007) showing that HIF-1α accumulation was 
mediated by classical PKC isoforms as well as phosphorylation of Akt, ERK, 4E-BP1 
and p70S6K in lung cancer cells. 
In addition, hypoxia is known to increase the stability of HIF-1α by inhibiting 
the activity of PHDs and hence the interaction between HIF-1α and the pVHL complex 
(Semenza 2003). Thus, the possibility of S1P having an effect on the stability of HIF-
1α was investigated. By performing chase-experiments with cycloheximide (CHX) and 
study its effect on the S1P, CoCl2 and hypoxia induced HIF-1α, it was found that S1P, in 
fact, also increased the stability of HIF-1α. This response turned out to be independent 
of pVHL, since S1P-induced HIF-1α was still bound to pVHL in pull-down experiments 
even though S1P decreased the hydroxylation of HIF-1α on pro402. S1P had, however, no 
effect on pro506 residue. Both Hsp90 and RACK1 were previously shown to participate 
in stabilization of HIF-1α. Binding to Hsp90 stabilizes HIF-1α, while HIF-1α is destined 
for degradation when it binds to RACK1 (Liu et al., 2007). Thus, it was asked if Hsp90 
and RACK1 could have a role in regulating HIF-1α. Inhibition of Hsp90 did indeed 
prevent S1P from inducing HIF-1α protein, however, any changes in binding of HIF-1α 
to Hsp90 could not be observed due to technical difficulties. Taken together, S1P might 
increase both the translation and stability of HIF-1α, albeit the S1P-induced stability is 
not dependent on VHL. 
5.1.3 HIF-1α is involved in basal and S1P-induced ML-1 cell migration
Since S1P treatment increased HIF-1α expression in both ML-1 and FTC-133 cells, 
and many previously published data showed that HIF-1α is important for migration 
(Semenza, 2003) it was interesting to explore the role of HIF-1α in S1P-induced 
migration. For this purpose both small molecular inhibitors and siRNA against HIF-
1α were used, and it was found that inhibition of HIF-1α in both ML-1 and FTC-
133 cells with small molecular inhibitors could abolish S1P-induced cell migration. 
However, results from siRNA experiments showed that silencing of HIF-1α could 
decrease basal migration. Interestingly, siRNA against HIF-1α was not able to totally 
abolish the S1P-induced migration, suggesting that there might be other players in 
S1P-regulated migration. Migration experiments were also performed under hypoxic 
conditions, as hypoxia is known to induce migration by up-regulating HIF-1α. 
Surprisingly, neither basal migration nor S1P-induced migration could be induced in 
hypoxia. It was hypothesized that hypoxia might inhibit unknown factors important 
for migration and S1P-signaling, explaining the responses observed. Taken together, it 
can be concluded that S1P up-regulates HIF-1α by increasing both stability and protein 
synthesis. Furthermore, HIF-1α regulates basal ML-1 migration and, in part, S1P-
induced migration. Thus, inhibition of HIF-1α might serve as a favorable therapeutic 
approach for thyroid cancer patients.
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5.2 MMP2 and MMP9 are involved in S1P-induced invasion of ML-1 
cells (II)
5.2.1 The effect of S1P on the secretion, activity and expression of MMP2 and MMP9
Matrix metalloproteinases are degrading enzymes of the extracellular matrix facilitating 
cell migration and invasion of several types of cancer cells (Folgueras et al., 2004). 
Especially MMP2 and MMP9 have been shown to regulate migration and invasion of 
ML-1 cells (Rajoria et al., 2011). It was earlier shown that S1P is a potent inducer of 
ML-1 cell migration (Balthasar et al., 2006) leading to the speculation that MMP2 and 
MMP9 might be of importance for S1P-induced invasion of ML-1 cells. The results 
showed that S1P caused a rapid increase of both MMP2 and MMP9 secretion and 
activity. However, long incubation of cells with S1P (48 h) resulted in an increase only 
in MMP2 expression. In addition, results showed that S1P modulated MMP2 and MMP9 
via S1P1,3. These results were in line with previously published data that showed S1P 
to enhance the secretion, activity and expression of MMP2 and MMP9 (Devine et al., 
2008; Sun et al., 2010; Kim et al., 2011;). Thus, S1P evokes expression, secretion and 
activity of MMP2 and 9 in ML-1 cells. 
5.2.2 MMP2 and MMP9 participate in S1P-evoked invasion of ML-1 cells
As we had previously shown that S1P strongly induces migration of ML-1 cells (Balthasar 
et al., 2006), and that S1P enhances MMP2 and MMP9 secretion and activity, it was asked 
whether these two MMPs are mediators of S1P-evoked invasion. Both pharmacological 
inhibitors and siRNA against MMP2 and MMP9 were used. The inhibitors were able to 
totally abolish S1P-induced invasion. The results from siRNA experiments, however, 
showed that despite a substantial down-regulation of the expression and activity of MMP2 
and MMP9, S1P could not be completely prevented from inducing invasion. This led to 
the assumption that other ECM-degrading enzymes might be involved in the S1P-evoked 
invasion of ML-1 cells. As the MMP family has many other members (Stamenkovic, 
2000), the effect of S1P on MMP1, MMP3, MMP8 and MMP13 was tested. S1P had either 
no effect on the secretion or expression of these, or these proteins could not be detected in 
our investigations. In addition to MMPs, there are many other ECM-degrading enzymes 
that facilitate migration and invasion. The secretion of kallikreins (Romero Otero et al., 
2014) and uPA (Noh et al., 2013) were investigated, however, these were not detected in 
the collected medium. The effect of S1P on the expression of matriptase (Miller & List 
2013), LOX (Mayorca-Guiliani & Erler, 2013), and uPAR (Noh et al., 2013) were also 
studied, however, S1P was without any effect on these enzymes. Taken together, MMP2 
and MMP9 participate in ML-1 cell invasion evoked by S1P, albeit there might also be 
other players, yet to be identified, in this regulation.
5.2.3 Calpains and Rac1 mediate S1P-induced secretion of MMP2 and MMP9
Previous findings showed that calpains are involved in cleaving several different proteins 
(Storr et al., 2011) including MMPs (Kang et al., 2011; Kwak et al., 2012). Furthermore, 
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S1P was demonstrated to activate calpains in human hepatocarcinoma cells (Chen et al., 
2013). These observations raised interests to investigate the effect of S1P on calpains, 
and the involvement of calpains in both invasion and MMP regulation. Evidence could 
be provided that S1P could rapidly increase the activity of calpains time-dependently. 
Inhibition of calpains by ALLN resulted in both attenuation of invasion and secretion 
of MMP2 and MMP9. Rac1 (Ras-related C3 botulinum toxin substrate 1) is involved 
in migration and invasion by forming lamellipodia in the rare side of a migrating cell 
(Murali & Rajalingam, 2014). Previously, it was shown that Rac1 mediated the S1P-
induced migration of ML-1 cells (Balthasar et al., 2006). In addition Rac1 was shown by 
Devine et al. (2008) to be involved in S1P-evoked regulation of MMPs. Based on these 
findings, we speculated that Rac1 could potentially be a mediator of the S1P-effect on 
MMPs in ML-1 cells. As expected, inhibition of Rac1 attenuated the S1P-evoked MMP2 
and MMP9 secretion. In conclusion, calpains and Rac1 participate in S1P-evoked MMP2 
and MMP9 secretion and invasion.
5.3 FTY720 (Fingolimod) attenuates thyroid cancer cell invasion and 
proliferation (III)
5.3.1 FTY720 modulates S1P-receptors
FTY720 is a S1P receptor modulating drug, which has been shown to cause internalization 
and degradation of S1P1,3 (Oo et al., 2007; Mousseau et al., 2012). As expected, in ML-1 
cells FTY720 evoked down-regulation of S1P1 in a time- and concentration dependent 
manner. However, the expression of S1P3 was inhibited only by high concentrations 
of FTY720. The FTY720-triggered down-regulation of S1P1 was due to lysosomal 
degradation. In contrast to our results, Oo et al. (2007) demonstrated that FTY720 
caused proteasomal degradation of S1PR1/3 in HUVEC and embryonic kidney 293 cells. 
Interestingly, it was found that S1P1 in untreated cells was degraded in the proteasome, 
pointing to a role for the proteasome in the fine-tuning of cellular levels of S1P1 protein. 
Taken together, FTY720 induces lysosomal degradation of S1P1, while under normal 
conditions S1P1 is degraded in the proteasome. Moreover, high concentrations of 
FTY720 are needed in order to be able to down-regulate S1P3, perhaps due to the fact 
that FTY720 might have a weaker binding affinity for S1P3. 
5.3.2 FTY720 inhibits invasion of thyroid cancer cells
It was previously shown that S1P and SK1 strongly evoked migration and invasion 
of ML-1 cells via S1P1,3 (Balthasar et al., 2006; Bergelin et al., 2009). Therefore, the 
role of FTY720 in migration of thyroid cells was investigated, and results showed that 
FTY720 attenuated invasion of several thyroid cancer cell lines, but was without an 
effect in normal thyroid cells. In addition, the S1P-induced invasion of both ML-1 and 
FTC-133 cells was significantly attenuated by FTY720. These results are strengthened 
by previously published data, which demonstrated that FTY720 inhibits migration 
of cancerous cells (Tonelli et al., 2010; Lim et al., 2011; Li et al., 2012; Mousseau et 
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al., 2012). Moreover, p-FTY720 could attenuate S1P-induced invasion of ML-1 cells. 
Previously it was shown that S1P induced invasion of ML-1 cells through VEGFR2, 
ERK1/2, PKCα and βI and HIF-1α (Balthasar et al., 2006, Balthasar et al., 2008). 
Accordingly, FTY720 inhibited the expression of VEGFR2, PKCα and -βI. However, 
FTY720 was not able to significantly decrease the expression of HIF-1α. Furthermore, 
FTY720 inhibited MMP2/9 activity and abolished S1P-induced MMP2/9 secretion and 
ERK1/2 phosphorylation in ML-1 cells. Surprisingly, FTY720 was not able to affect the 
expression of SK1, p70S6K or mTOR, all signaling intermediates inhibited by FTY720 
in other cancer cell types (Tonelli et al., 2010; Zhang et al., 2010). Taken together, 
FTY720 blocked migration by inhibiting signaling intermediates important for thyroid 
cancer cell migration. However, the final outcome of the FTY720 treatment depends on 
the concentration of the drug and the cancer cell type it is administered to, suggesting the 
importance of cancer cell specificity. 
5.3.3 FTY720 attenuates proliferation of thyroid cancer cells
Different concentrations of FTY720 were evaluated on the proliferation of thyroid 
cells and could show that FTY720 inhibited proliferation of all cell lines tested in a 
concentration dependent fashion. To further investigate the underlying mechanism 
behind this inhibition, ML-1 and FTC-133 cells were used, and it was found that 
FTY720 arrested cells in G1 phase and decreased the amount of cells in the S phase of 
the cell cycle in both cell lines. In ML-1 cells, the FTY720-evoked G1 arrest was due 
to an up-regulation of p21 and p27. These results were in accordance with previously 
published data by Permpongkosol et al. (2002), who demonstrated that FTY720 blocked 
proliferation of human prostate carcinoma DU145 cells by inducing apoptosis, and 
arresting cells in the G1 phase of the cell cycle through induction of p21. Combination 
therapy with several different drugs in treating cancer is emerging as a powerful tool 
to enhance the efficiency of the drugs. Therefore, cells were treated with FTY720 or 
p-FTY720 in combination with doxorubicin. However, it was not possible to see any 




Based on the results from these three studies, we conclude that:
1. HIF-1α is a mediator of S1P-induced migration in ML-1 and FTC-133 cells.
2. MMP2 and MMP9 participate in S1P-evoked invasion.
3. FTY720 could function as a promising inhibitor of thyroid cancer cell proliferation 
and invasion, by blocking signaling intermediates important for these processes. 
Figure 9. Schematic picture, demonstrating the involvement of HIF-1α and MMP2/9 in S1P-
induced pathology of follicular ML-1 thyroid cancer cells. 
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